celecoxib and Colorectal Cancer studies

Research Excerpts

Excerpt	Relevance	Reference
"Neoadjuvant toripalimab with or without celecoxib could be a potential therapeutic option for patients with mismatch repair deficient or microsatellite instability-high, locally advanced, colorectal cancer."	9.51	Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trial ( Cai, Y; Cao, W; Deng, W; Deng, Y; Dou, R; He, X; Hu, H; Hu, J; Huang, L; Huang, M; Huang, Y; Kang, L; Lan, P; Ling, J; Ling, L; Liu, H; Luo, S; Ma, T; Shen, C; Shi, L; Wang, C; Wang, H; Wu, X; Wu, Z; Xie, X; Zhang, J; Zhang, X; Zhou, J, 2022)
"Oxylipins derived from arachidonic acid (ARA) have been implicated in the development of colorectal adenomas and colorectal cancer."	9.41	A Protective Role for Arachidonic Acid Metabolites against Advanced Colorectal Adenoma in a Phase III Trial of Selenium. ( Chew, WM; Chow, HS; Ellis, NA; Jacobs, ET; Lance, P; Martinez, JA; Saboda, K; Skiba, MB, 2021)
"Celecoxib was unable to prevent oxaliplatin-related vascular pain in this study."	9.30	Randomized phase II trial of the prophylactic use of celecoxib for the prevention of oxaliplatin-related peripheral vascular pain in Capeox (YCOG1205). ( Endo, I; Ishibe, A; Momiyama, M; Nagamine, K; Ota, M; Saigusa, Y; Saito, S; Suwa, H; Suwa, Y; Suzuki, S; Watanabe, J; Watanabe, K; Yamanaka, T, 2019)
"The Selenium and Celecoxib Trial was a randomized, placebo-controlled trial of once-daily selenium 200 µg and celecoxib 400 mg, alone or together, for colorectal adenoma prevention."	9.22	Celecoxib for the Prevention of Colorectal Adenomas: Results of a Suspended Randomized Controlled Trial. ( Ahnen, DJ; Alberts, DS; Ashbeck, EL; Bhattacharyya, A; Boland, CR; Buckmeier, J; Chow, SH; Fales, L; Fay, DE; Hamilton, SR; Heigh, RI; Hsu, CH; Jacobs, ET; Lance, P; Martinez, EM; Roe, DJ; Thompson, PA; Wang, F, 2016)
"Chemoprevention trials have shown that celecoxib reduces adenoma recurrence but can cause cardiovascular toxicity."	9.17	Impact of genetic polymorphisms on adenoma recurrence and toxicity in a COX2 inhibitor (celecoxib) trial: results from a pilot study. ( Arber, N; Coghill, AE; Duggan, D; Galazan, L; Gigic, B; Hummler, S; Kazanov, D; Kotzmann, J; Kraus, S; Makar, KW; Naumov, I; Poole, EM; Scherer, D; Toriola, AT; Ulrich, CM, 2013)
" From August 2008 to December 2010, stage II and III colorectal cancer patients receiving capecitabine-based chemotherapy enrolled in the trial voluntarily."	9.16	Celecoxib can prevent capecitabine-related hand-foot syndrome in stage II and III colorectal cancer patients: result of a single-center, prospective randomized phase III trial. ( Chen, G; Kong, LH; Lu, ZH; Pan, ZZ; Wan, DS; Wu, XJ; Zhang, RX, 2012)
"COX inhibitors reduce colorectal adenoma recurrence by up to 45% and selenium supplementation may prevent colorectal cancer."	9.16	Design and baseline characteristics of participants in a phase III randomized trial of celecoxib and selenium for colorectal adenoma prevention. ( Ahnen, DJ; Alberts, DS; Ashbeck, EL; Bhattacharyya, A; Boland, CR; Buckmeier, J; Chow, HH; Fales, L; Fay, DE; Green, S; Hamilton, SR; Heigh, RI; Hsu, CH; Jacobs, E; Lance, P; Martinez, ME; Roe, DJ; Thompson, P; Wang, F, 2012)
" The Adenoma Prevention with Celecoxib (APC) trial showed that the anti-inflammatory drug celecoxib prevents recurrence of colorectal adenoma but increases risk of cardiovascular events."	9.15	C-reactive protein and risk of colorectal adenoma according to celecoxib treatment. ( Bertagnolli, MM; Chan, AT; Hawk, ET; Ridker, PM; Sima, CS; Zauber, AG, 2011)
"This study investigated the antitumour and chemosensitizing effects of celecoxib in the treatment of advanced colorectal cancer."	9.15	Observation of curative efficacy and prognosis following combination chemotherapy with celecoxib in the treatment of advanced colorectal cancer. ( Chen, JM; Jin, CH; Li, RX; Liu, XM; Wang, AH; Wang, GP; Xing, LQ, 2011)
"We identified individuals with CYP2C92 and CYP2C93 genotypes (>or=1 variant allele) in the Adenoma Prevention with Celecoxib trial."	9.14	Cytochrome P450 2C9 variants influence response to celecoxib for prevention of colorectal adenoma. ( Bertagnolli, MM; Breazna, A; Chan, AT; Eagle, CJ; Hawk, ET; Hsu, M; Hunter, DJ; Rosenstein, RB; Zauber, AG, 2009)
"The Adenoma Prevention with Celecoxib Trial examined the efficacy and safety of the cyclooxygenase (Cox)-2 inhibitor, celecoxib, for sporadic colorectal adenoma prevention in patients at high risk for colorectal cancer."	9.14	Five-year efficacy and safety analysis of the Adenoma Prevention with Celecoxib Trial. ( Bagheri, D; Bertagnolli, MM; Breazna, A; Burn, J; Chung, DC; Collins, NT; Dewar, T; Eagle, CJ; Foley, TR; Hawk, ET; Hoffman, N; Kim, K; Macrae, F; Pruitt, RE; Redston, M; Rosenstein, RB; Saltzman, JR; Salzberg, B; Sylwestrowicz, T; Tang, J; Umar, A; Zauber, AG, 2009)
"Irinotecan-based chemotherapy regimens are 1 option for treatment of metastatic colorectal cancer (mCRC)."	9.14	Comparing safety and efficacy of first-line irinotecan/fluoropyrimidine combinations in elderly versus nonelderly patients with metastatic colorectal cancer: findings from the bolus, infusional, or capecitabine with camptostar-celecoxib study. ( Barrueco, J; Jackson, NA; Marshall, J; Meyerhardt, J; Mitchell, E; Soufi-Mahjoubi, R; Zhang, X, 2009)
" A Phase-II study was undertaken to determine the activity of a dose attenuated schedule of irinotecan, capecitabine, and the COX-2 inhibitor celecoxib in patients with advanced colorectal cancer."	9.13	Phase-II study of dose attenuated schedule of irinotecan, capecitabine, and celecoxib in advanced colorectal cancer. ( El-Rayes, BF; Ferris, AM; Heilbrun, LK; Manza, SG; Philip, PA; Rusin, B; Shields, AF; Vaishampayan, U; Venkatramanamoorthy, R; Zalupski, MM, 2008)
"The study aimed to demonstrate the noninferiority of capecitabine to 5-fluorouracil (5-FU)/folinic acid (FA), in relation to progression-free survival (PFS) after first-line treatment of metastatic colorectal cancer and the benefit of adding celecoxib (C) to irinotecan/fluoropyrimidine regimens compared with placebo (P)."	9.13	Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015. ( Becker, K; Bethe, U; Bleiberg, H; Bokemeyer, C; Braumann, D; De Greve, J; Debois, M; Hartmann, JT; Janssens, J; Joosens, E; Köhne, CH; Lang, I; Link, H; Müller, L; Reimer, P; Späth-Schwalbe, E; Van Cutsem, E; Van Den Brande, J; Vergauwe, P; Wilke, HJ, 2008)
"COX-2 activation may mediate capecitabine induced toxicities, eg, hand-foot syndrome (HFS) and colorectal cancer progression, both of which may be improved by concurrent celecoxib."	9.12	Retrospective study of capecitabine and celecoxib in metastatic colorectal cancer: potential benefits and COX-2 as the common mediator in pain, toxicities and survival? ( Ayers, GD; Brown, T; Crane, CC; Curley, SA; Delcos, M; Feig, B; Janjan, N; Lin, EH; Morris, J; Rodriguez-Bigas, MA; Ross, A; Skibber, J; Vadhan, SR, 2006)
"The aim of the study was to verify the efficacy and safety of the addition of celecoxib to FOLFIRI combination therapy in patients affected by advanced colorectal cancer."	9.12	FOLFIRI with or without celecoxib in advanced colorectal cancer: a randomized phase II study of the Gruppo Oncologico dell'Italia Meridionale (GOIM). ( Colucci, G; Di Renzo, N; Gebbia, V; Giuliani, F; Lopez, M; Maiello, E; Mallamaci, R; Pezzella, G; Romito, S, 2006)
"The Adenoma Prevention With Celecoxib (APC) trial studied celecoxib 200 mg twice daily and 400 mg twice daily and the Prevention of Spontaneous Adenomatous Polyps (PreSAP) trial used 400 mg once daily totest the efficacy and safety of celecoxib against placebo in reducing colorectal adenoma recurrence after polypectomy."	9.12	Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas. ( Arber, N; Bertagnolli, MM; Eagle, C; Finn, P; Fowler, R; Hawk, E; Lechuga, M; Levin, B; McMurray, JJ; Pfeffer, MA; Solomon, SD; Wittes, J; Zauber, AG, 2006)
"We randomly assigned patients who had adenomas removed before study entry to receive placebo (679 patients) or 200 mg (685 patients) or 400 mg (671 patients) of celecoxib twice daily."	9.12	Celecoxib for the prevention of sporadic colorectal adenomas. ( Anderson, WF; Bagheri, D; Bertagnolli, MM; Boisserie, F; Burn, J; Chung, DC; Corle, D; Dewar, T; Eagle, CJ; Foley, TR; Gordon, GB; Hawk, ET; Hess, TM; Hoffman, N; Kim, K; Macrae, F; Pruitt, RE; Redston, M; Rosenstein, RB; Saltzman, JR; Salzberg, B; Solomon, SD; Sylwestrowicz, T; Tang, J; Viner, JL; Wittes, J; Woloj, GM; Zauber, AG, 2006)
"The Prevention of Colorectal Sporadic Adenomatous Polyps trial was a randomized, placebo-controlled, double-blind study of the COX-2 inhibitor celecoxib given daily in a single 400-mg dose."	9.12	Celecoxib for the prevention of colorectal adenomatous polyps. ( Arber, N; Bhadra, P; Dite, P; Eagle, CJ; Fowler, R; Gerletti, P; Hajer, J; Lechuga, MJ; Levin, B; Macdonald, K; Rácz, I; Rosenstein, RB; Solomon, SD; Spicak, J; Tang, J; Wittes, J; Zauber, AG; Zavoral, M, 2006)
"Oxaliplatin stop and go in combination with leucovorin and 5-fluorouracil has been successfully used in a previous study (OPTIMOX1) in metastatic colorectal cancer (MCR)."	9.12	Phase II study of an optimized 5-fluorouracil-oxaliplatin strategy (OPTIMOX2) with celecoxib in metastatic colorectal cancer: a GERCOR study. ( André, T; Bidard, FC; de Gramont, A; Fellague-Chebra, R; Flesch, M; Hebbar, M; Louvet, C; Mabro, M; Mineur, L; Postel Vinay, S; Tournigand, C, 2007)
" Glutamine may decrease chemotherapy-associated diarrhea."	9.11	A phase II trial of irinotecan, 5-fluorouracil and leucovorin combined with celecoxib and glutamine as first-line therapy for advanced colorectal cancer. ( Ansari, R; Cheng, L; Helft, P; Juliar, B; Loehrer, P; Pan, CX; Pletcher, W; Seitz, D; Sweeney, C; Vinson, J, 2005)
"Discovery phase: 1,406 Caucasian patients (139 advanced adenoma cases and 1,267 controls) from the Adenoma Prevention with Celecoxib (APC) trial were included in a genome-wide association study (GWAS) to identify variants associated with postpolypectomy disease recurrence."	8.89	Germline variants and advanced colorectal adenomas: adenoma prevention with celecoxib trial genome-wide association study. ( Baird, PN; Bertagnolli, MM; Carvajal-Carmona, LG; Chu, JH; Dunlop, M; Gibbs, P; Houlston, RS; Kubo, M; Lipton, L; Martin, NG; Matsuda, K; Montgomery, GW; Nakamura, Y; Ratain, MJ; Sieber, O; Tomlinson, I; Wang, J; Weiss, ST; Young, J; Zauber, AG, 2013)
"Observational studies have found a decreased rate of colorectal cancer in people who regularly took aspirin or other nonsteroidal antiinflammatory drugs (NSAIDs)."	8.81	Celecoxib as adjunctive therapy for treatment of colorectal cancer. ( North, GL, 2001)
"Colorectal cancer has been found to be attenuated either with prophylactic manipulation of gut microbiome with probiotics or celecoxib, a non-steroidal anti-inflammatory drug mainly by suppressing early pro-carcinogenic markers in various experimental studies."	7.88	Prophylactic intervention of probiotics (L.acidophilus, L.rhamnosus GG) and celecoxib modulate Bax-mediated apoptosis in 1,2-dimethylhydrazine-induced experimental colon carcinogenesis. ( Chandel, D; Sharaf, LK; Sharma, M; Shukla, G, 2018)
"Here we showed that the addition of the COX-2 inhibitor celecoxib improved the antitumor efficacy in colorectal cancer (CRC) of the monoclonal anti-EGFR antibody cetuximab."	7.85	The addition of celecoxib improves the antitumor effect of cetuximab in colorectal cancer: role of EGFR-RAS-FOXM1-β- catenin signaling axis. ( Aranda, E; Cañas, A; Conde, F; de la Haba-Rodríguez, J; Guil-Luna, S; Hernández, V; López-Sánchez, LM; Morales-Estévez, C; Peñarando, J; Rodríguez-Ariza, A; Valverde, A; Villar, C, 2017)
" The selective cyclooxygenase-2 inhibitor, celecoxib (CX), has been known to have antitumor and chemo-sensitizing effect in the treatment of colorectal cancer."	7.83	The effect of celecoxib and its combination with imatinib on human HT-29 colorectal cancer cells: Involvement of COX-2, Caspase-3, VEGF and NF-κB genes expression. ( Atari-Hajipirloo, S; Heydari, A; Kheradmand, F; Nikanfar, S; Noori, F, 2016)
" Sulindac and Celecoxib in the regulation of cell cycle checkpoints along with tumor suppressor proteins to achieve their chemopreventive effects in the initial stages of experimental colorectal cancer."	7.80	Sulindac and Celecoxib regulate cell cycle progression by p53/p21 up regulation to induce apoptosis during initial stages of experimental colorectal cancer. ( Piplani, H; Rana, C; Sanyal, SN; Vaiphei, K; Vaish, V, 2014)
" This study tried to investigate whether an apple oligogalactan (AOG) could enhance the growth inhibitory effect of celecoxib on colorectal cancer."	7.80	An apple oligogalactan potentiates the growth inhibitory effect of celecoxib on colorectal cancer. ( Chen, J; Li, Q; Li, Y; Liu, L; Mei, L; Mei, Q; Niu, Y; Sun, Y; Zhang, B; Zhang, R, 2014)
" The present study was designed to assess the synergistic antitumor effects of NPC-16, a novel polyamine naphthalimide conjugate, with celecoxib and to elucidate the mechanism of these effects on human colorectal cancer cells."	7.78	COX-2-independent induction of apoptosis by celecoxib and polyamine naphthalimide conjugate mediated by polyamine depression in colorectal cancer cell lines. ( Li, JH; Li, Q; Wang, CJ; Wang, JH; Xie, SQ; Zhang, YH; Zhao, J, 2012)
"Celecoxib selectively affects genes and pathways involved in inflammation and malignant transformation in tumor but not normal tissues, this may assist in the development of safer and more effective chemopreventive agents."	7.77	Gene expression following exposure to celecoxib in humans: pathways of inflammation and carcinogenesis are activated in tumors but not normal tissues. ( Arber, N; Domany, E; Kazanov, D; Kraus, S; Naumov, I; Sagiv, E; Shapira, S; Sheffer, M, 2011)
"Studies have indicated that aspirin chemoprevention may be effective in preventing colorectal cancer within the general population, and aspirin, celecoxib, and calcium may be effective in preventing adenomas within those people who have previously undergone polypectomy."	7.77	Cost-effectiveness of aspirin, celecoxib, and calcium chemoprevention for colorectal cancer. ( Carroll, C; Cooper, K; Hind, D; Logan, R; Squires, H; Tappenden, P, 2011)
" The present study explores the effects of p53-modulating agent CP-31398 alone and combined with celecoxib on azoxymethane-induced aberrant crypt foci (ACF) and colon adenocarcinomas in F344 rats."	7.75	Inhibition of azoxymethane-induced colorectal cancer by CP-31398, a TP53 modulator, alone or in combination with low doses of celecoxib in male F344 rats. ( Guruswamy, S; Kopelovich, L; Patlolla, JM; Rao, CV; Steele, VE; Swamy, MV, 2009)
"Celecoxib, a clinical non-steroidal anti-inflammatory drug, displays anticarcinogenic and chemopreventive activities in human colorectal cancers, although the mechanisms of apoptosis by celecoxib are poorly understood."	7.74	Celecoxib induces p53-PUMA pathway for apoptosis in human colorectal cancer cells. ( Chao, JI; Hsiao, PW; Liu, HF, 2008)
" Celecoxib has been shown to reduce human colorectal cancers."	7.74	Activation of p38 mitogen-activated protein kinase by celecoxib oppositely regulates survivin and gamma-H2AX in human colorectal cancer cells. ( Chang, CC; Chao, JI; Chiu, TH; Hsiao, PW; Liu, HF; Tsai, CM, 2007)
" The present study was designed to evaluate the inhibitory effects of the COX-2 inhibitor celecoxib on the growth of colorectal cancer liver metastases in a syngeneic rat model, CC531."	7.74	Celecoxib inhibits growth of tumors in a syngeneic rat liver metastases model for colorectal cancer. ( de Boeck, G; de Bruijn, EA; de Heer, P; Guertens, G; Junggeburt, JM; Koudijs, MM; Kuppen, PJ; Nagelkerke, JF; Sandel, MH; van de Velde, CJ, 2008)
"To evaluate the role of celecoxib on 15-lipoxygenase-1 (15-LOX-1) expression, protein levels, and rates of apoptosis in colorectal cancer cell lines."	7.73	Tumor-associated down-regulation of 15-lipoxygenase-1 is reversed by celecoxib in colorectal cancer. ( Arnoletti, JP; Bland, KI; Boedefeld, W; Frolov, A; Hawkins, A; Heslin, MJ; Soong, R; Urist, MM, 2005)
"Expression/activity of histidine decarboxylase, histamine content, and prostaglandin E2 (PGE2) production were analyzed in 33 colorectal cancer samples and in the HT29, Caco-2, and HCT116 colon cancer cell lines."	7.73	The role of cyclooxygenase-2 in mediating the effects of histamine on cell proliferation and vascular endothelial growth factor production in colorectal cancer. ( Bani, D; Capaccioli, S; Cianchi, F; Cortesini, C; Fabbroni, V; Fanti, E; Magnelli, L; Masini, E; Messerini, L; Perigli, G; Perna, F; Schiavone, N, 2005)
"The purpose of this study was to develop a biodegradable drug platform composed of chitosan and guar gum and to explore the possibility of using it for local adjuvant or neoadjuvant therapy of colorectal cancer."	7.73	Luminal delivery and dosing considerations of local celecoxib administration to colorectal cancer. ( Gati, I; Haupt, S; Kleinstern, J; Rubinstein, A; Zioni, T, 2006)
"The objective of the present study was to determine the influence of cyclooxygenase-2 (COX-2) inhibition by Celecoxib (CLX) in humans with distal colorectal adenocarcinoma (CRC) on serum and tumor levels of progastrin and gastrin and serum levels of proinflammatory cytokines (IL-8, TNF-alpha)."	7.73	Effects of cyclooxygenase-2 inhibition on serum and tumor gastrins and expression of apoptosis-related proteins in colorectal cancer. ( Bielanski, W; Burnat, G; Hahn, E; Karcz, D; Konturek, PC; Konturek, SJ; Rehfeld, J; Rembiasz, K; Tusinela, M, 2006)
" We undertook a retrospective study comparing the incidences of hand-foot syndrome in 67 patients with metastatic colorectal cancer who took capecitabine (Xeloda) with or without celecoxib."	7.71	Effect of celecoxib on capecitabine-induced hand-foot syndrome and antitumor activity. ( Ayers, GD; Lin, E; Morris, JS, 2002)
"For patients at high risk of colorectal cancer, statins do not protect against colorectal neoplasms and may even increase the risk of developing colorectal adenomas."	6.75	Statin use and colorectal adenoma risk: results from the adenoma prevention with celecoxib trial. ( Bertagnolli, MM; Eagle, CJ; Hawk, ET; Hsu, M; Zauber, AG, 2010)
"The celecoxib pre-treated samples showed decreased expression levels in multiple genes involved in cellular lipid and glutathione metabolism; changes associated with diminished cellular proliferation."	6.73	Celecoxib pre-treatment in human colorectal adenocarcinoma patients is associated with gene expression alterations suggestive of diminished cellular proliferation. ( Auman, JT; Church, R; Fleshman, JW; Lee, SY; Mcleod, HL; Watson, MA, 2008)
"Celecoxib has been associated with decreased gastrointestinal toxicity and improved chemotherapy tolerance in preclinical in vivo models, resulting in its investigation in CRC clinical trials."	6.45	Does celecoxib have a role in the treatment of patients with colorectal cancer? ( Fakih, MG; Rustum, YM, 2009)
"However, EPA has only modest anti-colorectal cancer (CRC) activity, when used alone."	5.62	Cyclooxygenase activity mediates colorectal cancer cell resistance to the omega-3 polyunsaturated fatty acid eicosapentaenoic acid. ( Coletta, PL; Hull, MA; Hutchinson, JM; Ingram, N; Loadman, PM; Marshall, C; Nicolaou, A; Perry, SL; Race, AD; Spencer, J; Volpato, M, 2021)
"Neoadjuvant toripalimab with or without celecoxib could be a potential therapeutic option for patients with mismatch repair deficient or microsatellite instability-high, locally advanced, colorectal cancer."	5.51	Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trial ( Cai, Y; Cao, W; Deng, W; Deng, Y; Dou, R; He, X; Hu, H; Hu, J; Huang, L; Huang, M; Huang, Y; Kang, L; Lan, P; Ling, J; Ling, L; Liu, H; Luo, S; Ma, T; Shen, C; Shi, L; Wang, C; Wang, H; Wu, X; Wu, Z; Xie, X; Zhang, J; Zhang, X; Zhou, J, 2022)
"Oxylipins derived from arachidonic acid (ARA) have been implicated in the development of colorectal adenomas and colorectal cancer."	5.41	A Protective Role for Arachidonic Acid Metabolites against Advanced Colorectal Adenoma in a Phase III Trial of Selenium. ( Chew, WM; Chow, HS; Ellis, NA; Jacobs, ET; Lance, P; Martinez, JA; Saboda, K; Skiba, MB, 2021)
"In patients with advanced colorectal cancer, we compared the efficacy of celecoxib at two different doses (200 mg twice day and 400 mg twice daily) with placebo."	5.41	Selective COX-2 inhibitors do not increase gastrointestinal reactions after colorectal cancer surgery: a systematic review and meta-analysis. ( Bai, H; Hu, T; Li, Y; Liu, CJ; Liu, F; Tang, W; Wang, D; Yin, L; Yin, X, 2023)
"In the comparison of carcinogenesis, the percentage of normal tissue (i."	5.40	Combinational chemoprevention effect of celecoxib and an oral antiangiogenic LHD4 on colorectal carcinogenesis in mice. ( Alam, F; Byun, Y; Chung, SW; Jeon, OC; Kim, JY; Kim, SY; Park, J; Son, WC, 2014)
"Paeonol is a major active extract from the root bark of Paeonia suffruticosa Andrews with anti‑inflammatory, anti-oxidant, anti-allergic, anti-oxidation and antitumor effects."	5.40	Paeonol exerts an anticancer effect on human colorectal cancer cells through inhibition of PGE₂ synthesis and COX-2 expression. ( Li, M; Tan, SY; Wang, XF, 2014)
"Celecoxib (CLX) is a highly hydrophobic cyclooxygenase-2 inhibitor that can reduce the incidence of colorectal polyps; however, the adverse cardiovascular effects limit its applicability."	5.39	In vitro characterization of a liposomal formulation of celecoxib containing 1,2-distearoyl-sn-glycero-3-phosphocholine, cholesterol, and polyethylene glycol and its functional effects against colorectal cancer cell lines. ( Banerjee, S; Erdoğ, A; Keskin, D; Putra Limasale, YD; Tezcaner, A, 2013)
" In HCT116 cells, celecoxib increased VEGF production with time-course and dose-response curves similar to those observed for the increase of the ER chaperone, GRP78."	5.37	Celecoxib induces cell apoptosis coupled with up-regulation of the expression of VEGF by a mechanism involving ER stress in human colorectal cancer cells. ( Chen, S; Du, H; Li, W; Wang, Y; Zhang, Y, 2011)
"Celecoxib was shown to induce apoptosis that was attenuated by ectopic Bcl-2 or Bax knockout."	5.36	Celecoxib-induced apoptosis is enhanced by ABT-737 and by inhibition of autophagy in human colorectal cancer cells. ( Huang, S; Sinicrope, FA, 2010)
" This may be clinically important as this dose of celecoxib can be achieved in human serum following standard anti-inflammatory dosing of 100 mg."	5.33	Celecoxib and curcumin additively inhibit the growth of colorectal cancer in a rat model. ( Arber, N; Giladi, N; Kazanov, D; Lev-Ari, S; Liberman, E; Sagiv, E; Shpitz, B, 2006)
"Celecoxib was unable to prevent oxaliplatin-related vascular pain in this study."	5.30	Randomized phase II trial of the prophylactic use of celecoxib for the prevention of oxaliplatin-related peripheral vascular pain in Capeox (YCOG1205). ( Endo, I; Ishibe, A; Momiyama, M; Nagamine, K; Ota, M; Saigusa, Y; Saito, S; Suwa, H; Suwa, Y; Suzuki, S; Watanabe, J; Watanabe, K; Yamanaka, T, 2019)
"The Selenium and Celecoxib Trial was a randomized, placebo-controlled trial of once-daily selenium 200 µg and celecoxib 400 mg, alone or together, for colorectal adenoma prevention."	5.22	Celecoxib for the Prevention of Colorectal Adenomas: Results of a Suspended Randomized Controlled Trial. ( Ahnen, DJ; Alberts, DS; Ashbeck, EL; Bhattacharyya, A; Boland, CR; Buckmeier, J; Chow, SH; Fales, L; Fay, DE; Hamilton, SR; Heigh, RI; Hsu, CH; Jacobs, ET; Lance, P; Martinez, EM; Roe, DJ; Thompson, PA; Wang, F, 2016)
"Chemoprevention trials have shown that celecoxib reduces adenoma recurrence but can cause cardiovascular toxicity."	5.17	Impact of genetic polymorphisms on adenoma recurrence and toxicity in a COX2 inhibitor (celecoxib) trial: results from a pilot study. ( Arber, N; Coghill, AE; Duggan, D; Galazan, L; Gigic, B; Hummler, S; Kazanov, D; Kotzmann, J; Kraus, S; Makar, KW; Naumov, I; Poole, EM; Scherer, D; Toriola, AT; Ulrich, CM, 2013)
" From August 2008 to December 2010, stage II and III colorectal cancer patients receiving capecitabine-based chemotherapy enrolled in the trial voluntarily."	5.16	Celecoxib can prevent capecitabine-related hand-foot syndrome in stage II and III colorectal cancer patients: result of a single-center, prospective randomized phase III trial. ( Chen, G; Kong, LH; Lu, ZH; Pan, ZZ; Wan, DS; Wu, XJ; Zhang, RX, 2012)
"COX inhibitors reduce colorectal adenoma recurrence by up to 45% and selenium supplementation may prevent colorectal cancer."	5.16	Design and baseline characteristics of participants in a phase III randomized trial of celecoxib and selenium for colorectal adenoma prevention. ( Ahnen, DJ; Alberts, DS; Ashbeck, EL; Bhattacharyya, A; Boland, CR; Buckmeier, J; Chow, HH; Fales, L; Fay, DE; Green, S; Hamilton, SR; Heigh, RI; Hsu, CH; Jacobs, E; Lance, P; Martinez, ME; Roe, DJ; Thompson, P; Wang, F, 2012)
" The Adenoma Prevention with Celecoxib (APC) trial showed that the anti-inflammatory drug celecoxib prevents recurrence of colorectal adenoma but increases risk of cardiovascular events."	5.15	C-reactive protein and risk of colorectal adenoma according to celecoxib treatment. ( Bertagnolli, MM; Chan, AT; Hawk, ET; Ridker, PM; Sima, CS; Zauber, AG, 2011)
"This study investigated the antitumour and chemosensitizing effects of celecoxib in the treatment of advanced colorectal cancer."	5.15	Observation of curative efficacy and prognosis following combination chemotherapy with celecoxib in the treatment of advanced colorectal cancer. ( Chen, JM; Jin, CH; Li, RX; Liu, XM; Wang, AH; Wang, GP; Xing, LQ, 2011)
"We identified individuals with CYP2C92 and CYP2C93 genotypes (>or=1 variant allele) in the Adenoma Prevention with Celecoxib trial."	5.14	Cytochrome P450 2C9 variants influence response to celecoxib for prevention of colorectal adenoma. ( Bertagnolli, MM; Breazna, A; Chan, AT; Eagle, CJ; Hawk, ET; Hsu, M; Hunter, DJ; Rosenstein, RB; Zauber, AG, 2009)
"The Adenoma Prevention with Celecoxib Trial examined the efficacy and safety of the cyclooxygenase (Cox)-2 inhibitor, celecoxib, for sporadic colorectal adenoma prevention in patients at high risk for colorectal cancer."	5.14	Five-year efficacy and safety analysis of the Adenoma Prevention with Celecoxib Trial. ( Bagheri, D; Bertagnolli, MM; Breazna, A; Burn, J; Chung, DC; Collins, NT; Dewar, T; Eagle, CJ; Foley, TR; Hawk, ET; Hoffman, N; Kim, K; Macrae, F; Pruitt, RE; Redston, M; Rosenstein, RB; Saltzman, JR; Salzberg, B; Sylwestrowicz, T; Tang, J; Umar, A; Zauber, AG, 2009)
"Irinotecan-based chemotherapy regimens are 1 option for treatment of metastatic colorectal cancer (mCRC)."	5.14	Comparing safety and efficacy of first-line irinotecan/fluoropyrimidine combinations in elderly versus nonelderly patients with metastatic colorectal cancer: findings from the bolus, infusional, or capecitabine with camptostar-celecoxib study. ( Barrueco, J; Jackson, NA; Marshall, J; Meyerhardt, J; Mitchell, E; Soufi-Mahjoubi, R; Zhang, X, 2009)
" A Phase-II study was undertaken to determine the activity of a dose attenuated schedule of irinotecan, capecitabine, and the COX-2 inhibitor celecoxib in patients with advanced colorectal cancer."	5.13	Phase-II study of dose attenuated schedule of irinotecan, capecitabine, and celecoxib in advanced colorectal cancer. ( El-Rayes, BF; Ferris, AM; Heilbrun, LK; Manza, SG; Philip, PA; Rusin, B; Shields, AF; Vaishampayan, U; Venkatramanamoorthy, R; Zalupski, MM, 2008)
"The study aimed to demonstrate the noninferiority of capecitabine to 5-fluorouracil (5-FU)/folinic acid (FA), in relation to progression-free survival (PFS) after first-line treatment of metastatic colorectal cancer and the benefit of adding celecoxib (C) to irinotecan/fluoropyrimidine regimens compared with placebo (P)."	5.13	Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015. ( Becker, K; Bethe, U; Bleiberg, H; Bokemeyer, C; Braumann, D; De Greve, J; Debois, M; Hartmann, JT; Janssens, J; Joosens, E; Köhne, CH; Lang, I; Link, H; Müller, L; Reimer, P; Späth-Schwalbe, E; Van Cutsem, E; Van Den Brande, J; Vergauwe, P; Wilke, HJ, 2008)
"COX-2 activation may mediate capecitabine induced toxicities, eg, hand-foot syndrome (HFS) and colorectal cancer progression, both of which may be improved by concurrent celecoxib."	5.12	Retrospective study of capecitabine and celecoxib in metastatic colorectal cancer: potential benefits and COX-2 as the common mediator in pain, toxicities and survival? ( Ayers, GD; Brown, T; Crane, CC; Curley, SA; Delcos, M; Feig, B; Janjan, N; Lin, EH; Morris, J; Rodriguez-Bigas, MA; Ross, A; Skibber, J; Vadhan, SR, 2006)
"The aim of the study was to verify the efficacy and safety of the addition of celecoxib to FOLFIRI combination therapy in patients affected by advanced colorectal cancer."	5.12	FOLFIRI with or without celecoxib in advanced colorectal cancer: a randomized phase II study of the Gruppo Oncologico dell'Italia Meridionale (GOIM). ( Colucci, G; Di Renzo, N; Gebbia, V; Giuliani, F; Lopez, M; Maiello, E; Mallamaci, R; Pezzella, G; Romito, S, 2006)
"The Adenoma Prevention With Celecoxib (APC) trial studied celecoxib 200 mg twice daily and 400 mg twice daily and the Prevention of Spontaneous Adenomatous Polyps (PreSAP) trial used 400 mg once daily totest the efficacy and safety of celecoxib against placebo in reducing colorectal adenoma recurrence after polypectomy."	5.12	Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas. ( Arber, N; Bertagnolli, MM; Eagle, C; Finn, P; Fowler, R; Hawk, E; Lechuga, M; Levin, B; McMurray, JJ; Pfeffer, MA; Solomon, SD; Wittes, J; Zauber, AG, 2006)
"We randomly assigned patients who had adenomas removed before study entry to receive placebo (679 patients) or 200 mg (685 patients) or 400 mg (671 patients) of celecoxib twice daily."	5.12	Celecoxib for the prevention of sporadic colorectal adenomas. ( Anderson, WF; Bagheri, D; Bertagnolli, MM; Boisserie, F; Burn, J; Chung, DC; Corle, D; Dewar, T; Eagle, CJ; Foley, TR; Gordon, GB; Hawk, ET; Hess, TM; Hoffman, N; Kim, K; Macrae, F; Pruitt, RE; Redston, M; Rosenstein, RB; Saltzman, JR; Salzberg, B; Solomon, SD; Sylwestrowicz, T; Tang, J; Viner, JL; Wittes, J; Woloj, GM; Zauber, AG, 2006)
"The Prevention of Colorectal Sporadic Adenomatous Polyps trial was a randomized, placebo-controlled, double-blind study of the COX-2 inhibitor celecoxib given daily in a single 400-mg dose."	5.12	Celecoxib for the prevention of colorectal adenomatous polyps. ( Arber, N; Bhadra, P; Dite, P; Eagle, CJ; Fowler, R; Gerletti, P; Hajer, J; Lechuga, MJ; Levin, B; Macdonald, K; Rácz, I; Rosenstein, RB; Solomon, SD; Spicak, J; Tang, J; Wittes, J; Zauber, AG; Zavoral, M, 2006)
"Oxaliplatin stop and go in combination with leucovorin and 5-fluorouracil has been successfully used in a previous study (OPTIMOX1) in metastatic colorectal cancer (MCR)."	5.12	Phase II study of an optimized 5-fluorouracil-oxaliplatin strategy (OPTIMOX2) with celecoxib in metastatic colorectal cancer: a GERCOR study. ( André, T; Bidard, FC; de Gramont, A; Fellague-Chebra, R; Flesch, M; Hebbar, M; Louvet, C; Mabro, M; Mineur, L; Postel Vinay, S; Tournigand, C, 2007)
"A combination of celecoxib and selenium was used in a randomized double-blind Phase II trial as a preliminary study to a multicenter Phase III colorectal cancer chemoprevention trial using these two agents together."	5.11	Effects of a high-selenium yeast supplement on celecoxib plasma levels: a randomized phase II trial. ( Alberts, DS; Choquette, K; Chow, HH; Fish, A; Francis, J; Frank, DH; Gracie, D; Guillen, JM; Roe, DJ, 2004)
" Glutamine may decrease chemotherapy-associated diarrhea."	5.11	A phase II trial of irinotecan, 5-fluorouracil and leucovorin combined with celecoxib and glutamine as first-line therapy for advanced colorectal cancer. ( Ansari, R; Cheng, L; Helft, P; Juliar, B; Loehrer, P; Pan, CX; Pletcher, W; Seitz, D; Sweeney, C; Vinson, J, 2005)
"Discovery phase: 1,406 Caucasian patients (139 advanced adenoma cases and 1,267 controls) from the Adenoma Prevention with Celecoxib (APC) trial were included in a genome-wide association study (GWAS) to identify variants associated with postpolypectomy disease recurrence."	4.89	Germline variants and advanced colorectal adenomas: adenoma prevention with celecoxib trial genome-wide association study. ( Baird, PN; Bertagnolli, MM; Carvajal-Carmona, LG; Chu, JH; Dunlop, M; Gibbs, P; Houlston, RS; Kubo, M; Lipton, L; Martin, NG; Matsuda, K; Montgomery, GW; Nakamura, Y; Ratain, MJ; Sieber, O; Tomlinson, I; Wang, J; Weiss, ST; Young, J; Zauber, AG, 2013)
"The treatment of metastatic colorectal cancer (mCRC) has changed dramatically from the 1980s, when only fluorouracil (5-FU) was available for treatment and the median survival was at best 12 months, to a time when mCRC is considered more of a chronic disease in which the median survival is now reported in excess of 2 years."	4.84	First-line therapeutic strategies in metastatic colorectal cancer. ( Davies, JM; Goldberg, RM, 2008)
" Thus, physiological and pathophysiological roles of COX-2 were considered from the standpoint of clinical effects of the two latest COX-2 selective inhibitors, celecoxib and rofecoxib, on inflammation, pain, fever and colorectal cancer together with their adverse effects on gastrointestinal, renal and platelet functions; and the usefulness and limits of COX-2-selective inhibitors were discussed with the trends of new NSAIDs development."	4.81	[Cyclooxygenase (COX)-2 selective inhibitors: aspirin, a dual COX-1/COX-2 inhibitor, to COX-2 selective inhibitors]. ( Nakamura, H, 2001)
"Observational studies have found a decreased rate of colorectal cancer in people who regularly took aspirin or other nonsteroidal antiinflammatory drugs (NSAIDs)."	4.81	Celecoxib as adjunctive therapy for treatment of colorectal cancer. ( North, GL, 2001)
"NSAIDs such as celecoxib and sulindac play a critical role in the treatment of colorectal cancer, yet it is not understood how sufficiently high concentrations are reached in colonic tissue."	4.02	Insight into the Colonic Disposition of Sulindac in Humans. ( Augustijns, P; Brouwers, J; Lemmens, G; Snoeys, J; Vanuytsel, T, 2021)
"Colorectal cancer has been found to be attenuated either with prophylactic manipulation of gut microbiome with probiotics or celecoxib, a non-steroidal anti-inflammatory drug mainly by suppressing early pro-carcinogenic markers in various experimental studies."	3.88	Prophylactic intervention of probiotics (L.acidophilus, L.rhamnosus GG) and celecoxib modulate Bax-mediated apoptosis in 1,2-dimethylhydrazine-induced experimental colon carcinogenesis. ( Chandel, D; Sharaf, LK; Sharma, M; Shukla, G, 2018)
"Here we showed that the addition of the COX-2 inhibitor celecoxib improved the antitumor efficacy in colorectal cancer (CRC) of the monoclonal anti-EGFR antibody cetuximab."	3.85	The addition of celecoxib improves the antitumor effect of cetuximab in colorectal cancer: role of EGFR-RAS-FOXM1-β- catenin signaling axis. ( Aranda, E; Cañas, A; Conde, F; de la Haba-Rodríguez, J; Guil-Luna, S; Hernández, V; López-Sánchez, LM; Morales-Estévez, C; Peñarando, J; Rodríguez-Ariza, A; Valverde, A; Villar, C, 2017)
" The selective cyclooxygenase-2 inhibitor, celecoxib (CX), has been known to have antitumor and chemo-sensitizing effect in the treatment of colorectal cancer."	3.83	The effect of celecoxib and its combination with imatinib on human HT-29 colorectal cancer cells: Involvement of COX-2, Caspase-3, VEGF and NF-κB genes expression. ( Atari-Hajipirloo, S; Heydari, A; Kheradmand, F; Nikanfar, S; Noori, F, 2016)
" Sulindac and Celecoxib in the regulation of cell cycle checkpoints along with tumor suppressor proteins to achieve their chemopreventive effects in the initial stages of experimental colorectal cancer."	3.80	Sulindac and Celecoxib regulate cell cycle progression by p53/p21 up regulation to induce apoptosis during initial stages of experimental colorectal cancer. ( Piplani, H; Rana, C; Sanyal, SN; Vaiphei, K; Vaish, V, 2014)
" This study tried to investigate whether an apple oligogalactan (AOG) could enhance the growth inhibitory effect of celecoxib on colorectal cancer."	3.80	An apple oligogalactan potentiates the growth inhibitory effect of celecoxib on colorectal cancer. ( Chen, J; Li, Q; Li, Y; Liu, L; Mei, L; Mei, Q; Niu, Y; Sun, Y; Zhang, B; Zhang, R, 2014)
" The present study was designed to assess the synergistic antitumor effects of NPC-16, a novel polyamine naphthalimide conjugate, with celecoxib and to elucidate the mechanism of these effects on human colorectal cancer cells."	3.78	COX-2-independent induction of apoptosis by celecoxib and polyamine naphthalimide conjugate mediated by polyamine depression in colorectal cancer cell lines. ( Li, JH; Li, Q; Wang, CJ; Wang, JH; Xie, SQ; Zhang, YH; Zhao, J, 2012)
"Celecoxib selectively affects genes and pathways involved in inflammation and malignant transformation in tumor but not normal tissues, this may assist in the development of safer and more effective chemopreventive agents."	3.77	Gene expression following exposure to celecoxib in humans: pathways of inflammation and carcinogenesis are activated in tumors but not normal tissues. ( Arber, N; Domany, E; Kazanov, D; Kraus, S; Naumov, I; Sagiv, E; Shapira, S; Sheffer, M, 2011)
"Studies have indicated that aspirin chemoprevention may be effective in preventing colorectal cancer within the general population, and aspirin, celecoxib, and calcium may be effective in preventing adenomas within those people who have previously undergone polypectomy."	3.77	Cost-effectiveness of aspirin, celecoxib, and calcium chemoprevention for colorectal cancer. ( Carroll, C; Cooper, K; Hind, D; Logan, R; Squires, H; Tappenden, P, 2011)
"Although evidence suggests that aspirin and celecoxib may reduce the risk of colorectal cancer (CRC), these drugs can also cause harmful side effects."	3.75	Patient preferences for the chemoprevention of colorectal cancer. ( Broughton, DE; Gazelle, GS; Hur, C; Kong, CY; Ozanne, EM; Richards, EB; Truong, T, 2009)
"This study aimed to observe the growth-inhibitory effect of PC-407 (4-[5-naphthyl-3-(trifluoromethyl)-1H-pyrazol-1-yl] benzenesulfonamide), a celecoxib derivative synthesized in our lab, in human colorectal cancer cells and a colitis-associated colorectal cancer (CACC) model, and investigate the relative molecular mechanisms."	3.75	PC-407, a celecoxib derivative, inhibited the growth of colorectal tumor in vitro and in vivo. ( Fan, L; Huang, H; Li, Q; Li, Y; Liu, L; Mei, Q; Niu, Y; Sun, Y; Wu, H; Zhang, B, 2009)
" The present study explores the effects of p53-modulating agent CP-31398 alone and combined with celecoxib on azoxymethane-induced aberrant crypt foci (ACF) and colon adenocarcinomas in F344 rats."	3.75	Inhibition of azoxymethane-induced colorectal cancer by CP-31398, a TP53 modulator, alone or in combination with low doses of celecoxib in male F344 rats. ( Guruswamy, S; Kopelovich, L; Patlolla, JM; Rao, CV; Steele, VE; Swamy, MV, 2009)
"Celecoxib, a clinical non-steroidal anti-inflammatory drug, displays anticarcinogenic and chemopreventive activities in human colorectal cancers, although the mechanisms of apoptosis by celecoxib are poorly understood."	3.74	Celecoxib induces p53-PUMA pathway for apoptosis in human colorectal cancer cells. ( Chao, JI; Hsiao, PW; Liu, HF, 2008)
"Elevated polyamine and nitric oxide levels (both derived from arginine) promote tumorigenesis, whereas non-steroidal anti-inflammatory drugs (NSAIDs) inhibit colorectal cancer (CRC) incidence in experimental and epidemiologic studies."	3.74	Risk and risk reduction involving arginine intake and meat consumption in colorectal tumorigenesis and survival. ( Anton-Culver, H; Besselsen, DG; Gerner, EW; Ignatenko, NA; Yerushalmi, HF; Zell, JA; Ziogas, A, 2007)
" Celecoxib has been shown to reduce human colorectal cancers."	3.74	Activation of p38 mitogen-activated protein kinase by celecoxib oppositely regulates survivin and gamma-H2AX in human colorectal cancer cells. ( Chang, CC; Chao, JI; Chiu, TH; Hsiao, PW; Liu, HF; Tsai, CM, 2007)
" The present study was designed to evaluate the inhibitory effects of the COX-2 inhibitor celecoxib on the growth of colorectal cancer liver metastases in a syngeneic rat model, CC531."	3.74	Celecoxib inhibits growth of tumors in a syngeneic rat liver metastases model for colorectal cancer. ( de Boeck, G; de Bruijn, EA; de Heer, P; Guertens, G; Junggeburt, JM; Koudijs, MM; Kuppen, PJ; Nagelkerke, JF; Sandel, MH; van de Velde, CJ, 2008)
" Twelve patients had 14 desmoid tumors: 7 were treated surgically and 7 medically (these patients received celecoxib and tamoxifen citrate therapy)."	3.73	Extracolonic manifestations of familial adenomatous polyposis after proctocolectomy. ( Goldman, G; Keidar, A; Klausner, JM; Rabau, M; Strul, H; Tulchinsky, H, 2005)
"To evaluate the role of celecoxib on 15-lipoxygenase-1 (15-LOX-1) expression, protein levels, and rates of apoptosis in colorectal cancer cell lines."	3.73	Tumor-associated down-regulation of 15-lipoxygenase-1 is reversed by celecoxib in colorectal cancer. ( Arnoletti, JP; Bland, KI; Boedefeld, W; Frolov, A; Hawkins, A; Heslin, MJ; Soong, R; Urist, MM, 2005)
"Expression/activity of histidine decarboxylase, histamine content, and prostaglandin E2 (PGE2) production were analyzed in 33 colorectal cancer samples and in the HT29, Caco-2, and HCT116 colon cancer cell lines."	3.73	The role of cyclooxygenase-2 in mediating the effects of histamine on cell proliferation and vascular endothelial growth factor production in colorectal cancer. ( Bani, D; Capaccioli, S; Cianchi, F; Cortesini, C; Fabbroni, V; Fanti, E; Magnelli, L; Masini, E; Messerini, L; Perigli, G; Perna, F; Schiavone, N, 2005)
"The purpose of this study was to develop a biodegradable drug platform composed of chitosan and guar gum and to explore the possibility of using it for local adjuvant or neoadjuvant therapy of colorectal cancer."	3.73	Luminal delivery and dosing considerations of local celecoxib administration to colorectal cancer. ( Gati, I; Haupt, S; Kleinstern, J; Rubinstein, A; Zioni, T, 2006)
"The objective of the present study was to determine the influence of cyclooxygenase-2 (COX-2) inhibition by Celecoxib (CLX) in humans with distal colorectal adenocarcinoma (CRC) on serum and tumor levels of progastrin and gastrin and serum levels of proinflammatory cytokines (IL-8, TNF-alpha)."	3.73	Effects of cyclooxygenase-2 inhibition on serum and tumor gastrins and expression of apoptosis-related proteins in colorectal cancer. ( Bielanski, W; Burnat, G; Hahn, E; Karcz, D; Konturek, PC; Konturek, SJ; Rehfeld, J; Rembiasz, K; Tusinela, M, 2006)
" We undertook a retrospective study comparing the incidences of hand-foot syndrome in 67 patients with metastatic colorectal cancer who took capecitabine (Xeloda) with or without celecoxib."	3.71	Effect of celecoxib on capecitabine-induced hand-foot syndrome and antitumor activity. ( Ayers, GD; Lin, E; Morris, JS, 2002)
"To use decision analysis to compare the cost-effectiveness of celecoxib to surveillance colonoscopy in 'average' risk patients who had undergone prior adenoma resection."	3.71	Surveillance colonoscopy or chemoprevention with COX-2 inhibitors in average-risk post-polypectomy patients: a decision analysis. ( Arguedas, MR; Heudebert, GR; Wilcox, CM, 2001)
"Treatment with celecoxib for 6 months, with before-treatment and after-treatment videos posted to an intranet with an interactive site for scoring."	2.78	Global quantitative assessment of the colorectal polyp burden in familial adenomatous polyposis by using a web-based tool. ( Khalaf, R; Levin, B; Lynch, PM; Morris, JS; Posadas, J; Rodriguez-Bigas, MA; Ross, WA; Sepeda, VO; Shureiqi, I; Weber, DM, 2013)
"Aspirin use was not independently associated with recurrent adenoma (RR, 0."	2.77	The influence of UGT1A6 variants and aspirin use in a randomized trial of celecoxib for prevention of colorectal adenoma. ( Bertagnolli, MM; Chan, AT; Hawk, ET; Hsu, M; Zauber, AG, 2012)
"For patients at high risk of colorectal cancer, statins do not protect against colorectal neoplasms and may even increase the risk of developing colorectal adenomas."	2.75	Statin use and colorectal adenoma risk: results from the adenoma prevention with celecoxib trial. ( Bertagnolli, MM; Eagle, CJ; Hawk, ET; Hsu, M; Zauber, AG, 2010)
"The celecoxib pre-treated samples showed decreased expression levels in multiple genes involved in cellular lipid and glutathione metabolism; changes associated with diminished cellular proliferation."	2.73	Celecoxib pre-treatment in human colorectal adenocarcinoma patients is associated with gene expression alterations suggestive of diminished cellular proliferation. ( Auman, JT; Church, R; Fleshman, JW; Lee, SY; Mcleod, HL; Watson, MA, 2008)
"Celecoxib was administered as 400 mg, twice daily starting on day 2 of cycle 1."	2.73	Celecoxib and mucosal protection: translation from an animal model to a phase I clinical trial of celecoxib, irinotecan, and 5-fluorouracil. ( Cao, S; Creaven, PJ; Durrani, FA; Iyer, RV; Javle, MM; Lawrence, DD; Noel, DC; Pendyala, L; Rustum, YM; Smith, PF, 2007)
"Side effects, such as arrhythmia, angina pectoris, and nervous headache, were observed in the celecoxib 400 mg/d group."	2.72	[Clinical management of adenomatous polyposis in patients with hereditary non-polyposis colorectal cancer and familial adenomatous polyposis]. ( Geng, HG; Li, SR; Sheng, JQ; Su, H; Yan, W; Yang, XY; Yu, DL; Zhang, YH, 2006)
"Celecoxib was shown to regress colorectal adenomas in familial adenomatous polyposis (FAP) patients relative to placebo."	2.71	Cell proliferation and apoptotic indices predict adenoma regression in a placebo-controlled trial of celecoxib in familial adenomatous polyposis patients. ( Ayers, GD; Cohen, DS; Half, E; Hawk, ET; Levin, B; Lynch, PM; Morris, JS; Morrow, JD; Sinicrope, FA; Stephens, LC, 2004)
"Celecoxib use was associated with a dose-related increase in the composite end point of death from cardiovascular causes, myocardial infarction, stroke, or heart failure."	2.71	Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. ( Anderson, WF; Bertagnolli, M; Finn, P; Fowler, R; Hawk, E; McMurray, JJ; Pfeffer, MA; Solomon, SD; Wittes, J; Zauber, A, 2005)
"Celecoxib has been associated with decreased gastrointestinal toxicity and improved chemotherapy tolerance in preclinical in vivo models, resulting in its investigation in CRC clinical trials."	2.45	Does celecoxib have a role in the treatment of patients with colorectal cancer? ( Fakih, MG; Rustum, YM, 2009)
"Recently, their potential roles as cancer chemopreventive agents have been subject to intensive studies."	2.44	Combination regimen with statins and NSAIDs: a promising strategy for cancer chemoprevention. ( Xiao, H; Yang, CS, 2008)
" However, recent studies showed that long term use of high doses of celecoxib is associated with an increased cardiovascular toxicity."	2.44	Compositions for treatment of cancer and inflammation. ( Arber, N; Lev-Ari, S; Lichtenberg, D, 2008)
"Mortality in patients with advanced colorectal cancer(CRC) remains high."	2.42	COX-2 inhibition and colorectal cancer. ( Dubois, RN; Koehne, CH, 2004)
" Epidemiologic data showed that chronic intake of traditional nonsteroidal anti-inflammatory drugs (NSAIDs) could reduce the incidence of colorectal cancer."	2.42	Prevention of colorectal cancer using COX-2 inhibitors: basic science and clinical applications. ( Chen, BD; Chou, TH; Chu, AJ, 2004)
"Chemoprevention strategies for colorectal cancer have gained increasing attention."	2.41	Chemoprevention in colorectal neoplasias: what is practical and feasible? ( Bazzoli, F; Ricciardiello, L; Roda, E, 2002)
" Herein, we assessed a combination of chidamide plus celecoxib (called CC-01) combined with programmed cell death protein 1 (PD-1) blockade in a CT26 model as potent tumor microenvironment (TME) regulator."	1.72	CC-01 (chidamide plus celecoxib) modifies the tumor immune microenvironment and reduces tumor progression combined with immune checkpoint inhibitor. ( Chao, YS; Chen, CN; Chen, JS; Chou, CH; Chu, SH; Wu, YH; Yang, MH, 2022)
"Celecoxib has been reported to reduce the incidence of colorectal adenomas and CRC but is also associated with an increased risk of cardiovascular events."	1.62	Gut-Restricted Selective Cyclooxygenase-2 (COX-2) Inhibitors for Chemoprevention of Colorectal Cancer. ( Bachman, KE; Bonnette, WG; Chen, H; Connolly, PJ; Dallas, S; Diloreto, KA; Dong, Y; Edwards, JP; Evans, DC; Ghosh, A; King, P; Li, X; Liao, D; Pande, V; Patel, S; Pietrak, B; Sensenhauser, C; Shi, Y; Suarez, J; Szewczuk, L; Tian, G; Wang, J; Wilde, T; Zhang, Z, 2021)
"However, EPA has only modest anti-colorectal cancer (CRC) activity, when used alone."	1.62	Cyclooxygenase activity mediates colorectal cancer cell resistance to the omega-3 polyunsaturated fatty acid eicosapentaenoic acid. ( Coletta, PL; Hull, MA; Hutchinson, JM; Ingram, N; Loadman, PM; Marshall, C; Nicolaou, A; Perry, SL; Race, AD; Spencer, J; Volpato, M, 2021)
"In the comparison of carcinogenesis, the percentage of normal tissue (i."	1.40	Combinational chemoprevention effect of celecoxib and an oral antiangiogenic LHD4 on colorectal carcinogenesis in mice. ( Alam, F; Byun, Y; Chung, SW; Jeon, OC; Kim, JY; Kim, SY; Park, J; Son, WC, 2014)
"Paeonol is a major active extract from the root bark of Paeonia suffruticosa Andrews with anti‑inflammatory, anti-oxidant, anti-allergic, anti-oxidation and antitumor effects."	1.40	Paeonol exerts an anticancer effect on human colorectal cancer cells through inhibition of PGE₂ synthesis and COX-2 expression. ( Li, M; Tan, SY; Wang, XF, 2014)
"Celecoxib is a COX-2 inhibitor drug that can be used to reduce the risk of colorectal adenocarcinoma."	1.39	A nitrophenyl-based prodrug type for colorectal targeting of prednisolone, budesonide and celecoxib. ( Gavin, J; Gilmer, JF; Kedziora, K; Kelleher, DP; Keogh, B; Marquez Ruiz, JF; Pigott, M; Windle, H, 2013)
"Celecoxib (CLX) is a highly hydrophobic cyclooxygenase-2 inhibitor that can reduce the incidence of colorectal polyps; however, the adverse cardiovascular effects limit its applicability."	1.39	In vitro characterization of a liposomal formulation of celecoxib containing 1,2-distearoyl-sn-glycero-3-phosphocholine, cholesterol, and polyethylene glycol and its functional effects against colorectal cancer cell lines. ( Banerjee, S; Erdoğ, A; Keskin, D; Putra Limasale, YD; Tezcaner, A, 2013)
" In HCT116 cells, celecoxib increased VEGF production with time-course and dose-response curves similar to those observed for the increase of the ER chaperone, GRP78."	1.37	Celecoxib induces cell apoptosis coupled with up-regulation of the expression of VEGF by a mechanism involving ER stress in human colorectal cancer cells. ( Chen, S; Du, H; Li, W; Wang, Y; Zhang, Y, 2011)
"Developing a strategy for preventing colorectal cancer by inhibiting COX-2 depends on research advances in several key areas, including predictive biomarkers to identify people at the lowest risk for cardiovascular events, the molecular mechanisms whereby interdicting the COX-2 pathway produces thrombotic events, and the pharmacology of the widely divergent agents that act on COX-2 and its downstream pathway."	1.37	Cardiovascular risk markers and mechanisms in targeting the COX pathway for colorectal cancer prevention. ( Oates, JA, 2011)
"Celecoxib was shown to induce apoptosis that was attenuated by ectopic Bcl-2 or Bax knockout."	1.36	Celecoxib-induced apoptosis is enhanced by ABT-737 and by inhibition of autophagy in human colorectal cancer cells. ( Huang, S; Sinicrope, FA, 2010)
"Early stages of colorectal cancer were produced in rats with 1,2-dimethylhydrazine dihydrochloride."	1.36	The role of NF-κB and PPARγ in experimentally induced colorectal cancer and chemoprevention by cyclooxygenase-2 inhibitors. ( Sanyal, SN; Tanwar, L; Vaish, V, 2010)
"Celecoxib has shown benefit in regressing colorectal adenomas and appears to have some duodenal activity as well."	1.35	Chemoprevention with special reference to inherited colorectal cancer. ( Lynch, PM, 2008)
"Celecoxib was also shown to work via cyclooxygenase-2 inhibition in transformed cells."	1.34	Gene expression analysis proposes alternative pathways for the mechanism by which celecoxib selectively inhibits the growth of transformed but not normal enterocytes. ( Arber, N; Kazanov, D; Liberman, E; Rozovski, U; Sagiv, E, 2007)
"Celecoxib was initiated in the diet at 100 ppm (equivalent to 20 mg/kg/d p."	1.33	Antitumor efficacy of capecitabine and celecoxib in irradiated and lead-shielded, contralateral human BxPC-3 pancreatic cancer xenografts: clinical implications of abscopal effects. ( Blanquicett, C; Buchsbaum, DJ; Carpenter, MD; Chhieng, DC; Diasio, RB; Eloubeidi, M; Johnson, MR; Russo, S; Saif, MW; Sellers, JC; Vickers, SM, 2005)
" This may be clinically important as this dose of celecoxib can be achieved in human serum following standard anti-inflammatory dosing of 100 mg."	1.33	Celecoxib and curcumin additively inhibit the growth of colorectal cancer in a rat model. ( Arber, N; Giladi, N; Kazanov, D; Lev-Ari, S; Liberman, E; Sagiv, E; Shpitz, B, 2006)
"Most colorectal cancers are believed to develop from colorectal adenomas."	1.32	The cyclooxygenase-2-selective inhibitors rofecoxib and celecoxib prevent colorectal neoplasia occurrence and recurrence. ( Bardou, M; Barkun, AN; Rahme, E; Toubouti, Y, 2003)
"The present study was designed to determine whether: (a) chronic administration of dietary celecoxib (Celebrex), a potent nonsteroidal anti-inflammatory drug, which targets the cyclooxygenase-2 (COX-2) enzyme, negatively impacts host immunity; and (b) celecoxib can be coupled with a poxvirus-based vaccine to impact tumor burden in a murine tumor model of spontaneous adenomatous polyposis coli."	1.32	Combination of a poxvirus-based vaccine with a cyclooxygenase-2 inhibitor (celecoxib) elicits antitumor immunity and long-term survival in CEA.Tg/MIN mice. ( Canter, D; Greiner, JW; Hursting, SD; Patel, AC; Rogers, CJ; Schlom, J; Zeytin, HE, 2004)
"The aspirin group also was modeled to have a decreased rate of coronary ischemic events; however, decreased CRC mortality was not modeled in either group based on the assumption that the two treatments were effective equally in this regard."	1.32	The cost-effectiveness of aspirin versus cyclooxygenase-2-selective inhibitors for colorectal carcinoma chemoprevention in healthy individuals. ( Gazelle, GS; Hur, C; Simon, LS, 2004)
"Celecoxib was the most effective anti-proliferative agent, and increased the G0/G1 phase proportion in the cell cycle after treatment more significantly than the other agents in all cell lines."	1.32	Comparison of the anti-proliferation and apoptosis-induction activities of sulindac, celecoxib, curcumin, and nifedipine in mismatch repair-deficient cell lines. ( Lin, YS; Tsao, PN; Wei, SC; Wong, JM; Wu, CH; Wu-Tsai, JJ, 2004)

Research

Studies (153)

Authors

Clinical Trials (14)

Trial Overview

Trial Outcomes

Median Selenium Blood Levels at One Year.

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	2 (1.31)	18.2507
2000's	88 (57.52)	29.6817
2010's	52 (33.99)	24.3611
2020's	11 (7.19)	2.80

Authors	Studies
Zhang, Z	1
Ghosh, A	1
Connolly, PJ	1
King, P	1
Wilde, T	1
Wang, J	2
Dong, Y	1
Li, X	1
Liao, D	1
Chen, H	1
Tian, G	1
Suarez, J	1
Bonnette, WG	1
Pande, V	1
Diloreto, KA	1
Shi, Y	1
Patel, S	1
Pietrak, B	1
Szewczuk, L	1
Sensenhauser, C	1
Dallas, S	1
Edwards, JP	1
Bachman, KE	1
Evans, DC	1
Hu, H	1
Kang, L	1
Zhang, J	1
Wu, Z	1
Wang, H	2
Huang, M	1
Lan, P	1
Wu, X	1
Wang, C	2
Cao, W	1
Hu, J	2
Huang, Y	1
Huang, L	2
Shi, L	1
Cai, Y	2
Shen, C	1
Ling, J	1
Xie, X	1
He, X	1
Dou, R	1
Zhou, J	1
Ma, T	1
Zhang, X	2
Luo, S	1
Deng, W	1
Ling, L	1
Liu, H	1
Deng, Y	1
Martinez, JA	1
Skiba, MB	1
Chow, HS	1
Chew, WM	1
Saboda, K	1
Lance, P	3
Ellis, NA	1
Jacobs, ET	2
Chen, JS	1
Chou, CH	1
Wu, YH	1
Yang, MH	1
Chu, SH	1
Chao, YS	1
Chen, CN	1
Wang, A	1
Shang, Y	1
Ni, J	1
Wang, W	1
Li, G	1
Chen, SZ	1
Hu, T	1
Liu, CJ	1
Yin, X	1
Tang, W	1
Yin, L	1
Bai, H	1
Liu, F	1
Wang, D	1
Li, Y	3
Pantalone, MR	1
Martin Almazan, N	1
Lattanzio, R	1
Taher, C	1
De Fabritiis, S	1
Valentinuzzi, S	1
Bishehsari, F	1
Mahdavinia, M	1
Verginelli, F	1
Rahbar, A	1
Mariani-Costantini, R	1
Söderberg-Naucler, C	1
Lemmens, G	1
Brouwers, J	1
Snoeys, J	1
Augustijns, P	1
Vanuytsel, T	1
Volpato, M	1
Ingram, N	1
Perry, SL	1
Spencer, J	1
Race, AD	1
Marshall, C	1
Hutchinson, JM	1
Nicolaou, A	1
Loadman, PM	1
Coletta, PL	1
Hull, MA	1
Ramanathan, R	1
Choudry, H	1
Jones, H	1
Girgis, M	1
Gooding, W	1
Kalinski, P	1
Bartlett, DL	1
Zhang, H	1
Chi, J	1
Ji, T	1
Luo, Z	1
Zhou, C	1
Dai, Z	1
Li, J	1
Wang, G	1
Wang, L	1
Wang, Z	1
Valverde, A	2
Peñarando, J	2
Cañas, A	2
López-Sánchez, LM	2
Conde, F	2
Guil-Luna, S	1
Hernández, V	2
Villar, C	1
Morales-Estévez, C	1
de la Haba-Rodríguez, J	2
Aranda, E	2
Rodríguez-Ariza, A	2
Alamdarsaravi, M	1
Ghajar, A	1
Noorbala, AA	1
Arbabi, M	1
Emami, A	1
Shahei, F	1
Mirzania, M	1
Jafarinia, M	1
Afarideh, M	1
Akhondzadeh, S	1
Gungor, H	2
Ilhan, N	2
Eroksuz, H	2
Mohammed, A	1
Yarla, NS	1
Madka, V	1
Rao, CV	2
Sharaf, LK	1
Sharma, M	1
Chandel, D	1
Shukla, G	1
Lin, YM	1
Lu, CC	1
Hsiang, YP	1
Pi, SC	1
Chen, CI	1
Cheng, KC	1
Pan, HL	1
Chien, PH	1
Chen, YJ	1
Suwa, Y	1
Watanabe, J	1
Ota, M	1
Suzuki, S	1
Suwa, H	1
Watanabe, K	1
Saito, S	1
Nagamine, K	1
Momiyama, M	1
Ishibe, A	1
Saigusa, Y	1
Yamanaka, T	1
Endo, I	1
Marquez Ruiz, JF	1
Kedziora, K	1
Pigott, M	1
Keogh, B	1
Windle, H	1
Gavin, J	1
Kelleher, DP	1
Gilmer, JF	1
Vaish, V	7
Piplani, H	3
Rana, C	3
Vaiphei, K	2
Sanyal, SN	7
Kraus, S	2
Hummler, S	1
Toriola, AT	1
Poole, EM	1
Scherer, D	1
Kotzmann, J	1
Makar, KW	1
Kazanov, D	5
Galazan, L	1
Naumov, I	2
Coghill, AE	1
Duggan, D	1
Gigic, B	1
Arber, N	8
Ulrich, CM	1
Erdoğ, A	1
Putra Limasale, YD	1
Keskin, D	1
Tezcaner, A	1
Banerjee, S	1
Carvajal-Carmona, LG	1
Chu, JH	1
Zauber, AG	9
Kubo, M	1
Matsuda, K	1
Dunlop, M	1
Houlston, RS	1
Sieber, O	1
Lipton, L	1
Gibbs, P	1
Martin, NG	1
Montgomery, GW	1
Young, J	1
Baird, PN	1
Ratain, MJ	1
Nakamura, Y	1
Weiss, ST	1
Tomlinson, I	1
Bertagnolli, MM	8
Niu, Y	2
Sun, Y	2
Mei, L	1
Zhang, B	2
Li, Q	3
Liu, L	2
Zhang, R	1
Chen, J	2
Mei, Q	2
Kim, JY	1
Alam, F	1
Chung, SW	1
Park, J	1
Jeon, OC	1
Kim, SY	1
Son, WC	1
Byun, Y	1
Shen, P	1
Zhang, XC	1
Zhao, MD	1
Zhang, XG	1
Yang, L	1
Li, M	1
Tan, SY	1
Wang, XF	1
Lönnroth, C	3
Andersson, M	3
Asting, AG	1
Nordgren, S	3
Lundholm, K	3
McDonald, BF	1
Quinn, AM	1
Devers, T	1
Cullen, A	1
Coulter, IS	1
Marison, IW	1
Loughran, ST	1
Peralbo, E	1
López-Pedrera, C	1
Wickström, M	1
Dyberg, C	1
Milosevic, J	1
Einvik, C	1
Calero, R	1
Sveinbjörnsson, B	1
Sandén, E	1
Darabi, A	1
Siesjö, P	1
Kool, M	1
Kogner, P	1
Baryawno, N	1
Johnsen, JI	1
Atari-Hajipirloo, S	1
Nikanfar, S	1
Heydari, A	1
Noori, F	1
Kheradmand, F	1
Gul, HF	1
Thompson, PA	2
Ashbeck, EL	2
Roe, DJ	3
Fales, L	2
Buckmeier, J	2
Wang, F	2
Bhattacharyya, A	2
Hsu, CH	2
Chow, SH	1
Ahnen, DJ	2
Boland, CR	2
Heigh, RI	2
Fay, DE	2
Hamilton, SR	2
Martinez, EM	1
Alberts, DS	3
Mohammadi, A	1
Yaghoobi, MM	1
GholamhoseynianNajar, A	1
Kalantari-Khandani, B	1
Sharifi, H	1
Saravani, M	1
Xiao, H	1
Yang, CS	1
Zrieki, A	1
Farinotti, R	1
Buyse, M	1
Auman, JT	1
Church, R	1
Lee, SY	1
Watson, MA	1
Fleshman, JW	1
Mcleod, HL	1
Liu, HF	2
Hsiao, PW	2
Chao, JI	2
Hur, C	2
Broughton, DE	1
Kong, CY	1
Ozanne, EM	1
Richards, EB	1
Truong, T	1
Gazelle, GS	2
Davies, JM	1
Goldberg, RM	1
Stevens, RG	1
Pretlow, TP	1
Hurlstone, DP	1
Giardina, C	1
Rosenberg, DW	1
Fakih, MG	1
Rustum, YM	2
Chan, AT	3
Hsu, M	3
Breazna, A	2
Hunter, DJ	1
Rosenstein, RB	4
Eagle, CJ	5
Hawk, ET	7
Dubois, RN	6
Redston, M	2
Kim, K	2
Tang, J	3
Umar, A	1
Bagheri, D	2
Collins, NT	1
Burn, J	2
Chung, DC	2
Dewar, T	2
Foley, TR	2
Hoffman, N	2
Macrae, F	2
Pruitt, RE	2
Saltzman, JR	2
Salzberg, B	2
Sylwestrowicz, T	2
Iguchi, G	1
Chrysovergis, K	1
Lee, SH	1
Baek, SJ	1
Langenbach, R	1
Eling, TE	1
Jackson, NA	1
Barrueco, J	1
Soufi-Mahjoubi, R	1
Marshall, J	1
Mitchell, E	1
Meyerhardt, J	1
Debucquoy, A	1
Devos, E	1
Vermaelen, P	1
Landuyt, W	1
De Weer, S	1
Van Den Heuvel, F	1
Haustermans, K	1
Wu, H	1
Huang, H	1
Fan, L	1
Steele, VE	1
Swamy, MV	1
Patlolla, JM	1
Guruswamy, S	1
Kopelovich, L	1
Huang, S	1
Sinicrope, FA	2
Tan, VP	1
Chan, P	1
Hung, IF	1
Pang, R	1
Wong, BC	1
Tanwar, L	2
Kaur, J	1
Meyskens, FL	1
McLaren, CE	1
Chan, E	1
Lafleur, B	1
Rothenberg, ML	1
Merchant, N	1
Lockhart, AC	1
Trivedi, B	1
Chung, CH	1
Coffey, RJ	1
Berlin, JD	1
Gerner, EW	2
Sagiv, E	3
Sheffer, M	1
Shapira, S	1
Domany, E	1
Du, H	1
Li, W	1
Wang, Y	1
Chen, S	1
Zhang, Y	1
Oates, JA	1
Sima, CS	1
Ridker, PM	1
Squires, H	1
Tappenden, P	1
Cooper, K	1
Carroll, C	1
Logan, R	1
Hind, D	1
Zhang, RX	1
Wu, XJ	1
Wan, DS	1
Lu, ZH	1
Kong, LH	1
Pan, ZZ	1
Chen, G	1
Xie, SQ	1
Zhang, YH	2
Wang, JH	1
Li, JH	1
Zhao, J	1
Wang, CJ	1
Jin, CH	1
Wang, AH	1
Chen, JM	1
Li, RX	1
Liu, XM	1
Wang, GP	1
Xing, LQ	1
Ockenga, J	1
Manzano, A	1
Pérez-Segura, P	1
Ninomiya, I	1
Nagai, N	1
Oyama, K	1
Hayashi, H	1
Tajima, H	1
Kitagawa, H	1
Fushida, S	1
Fujimura, T	1
Ohta, T	1
Thakkar, K	1
Fishman, DS	1
Gilger, MA	1
Thompson, P	1
Green, S	1
Chow, HH	2
Martinez, ME	1
Jacobs, E	1
Lynch, PM	4
Morris, JS	4
Ross, WA	1
Rodriguez-Bigas, MA	2
Posadas, J	1
Khalaf, R	1
Weber, DM	1
Sepeda, VO	1
Levin, B	4
Shureiqi, I	2
Ricciardiello, L	1
Roda, E	1
Bazzoli, F	1
Lin, E	1
Ayers, GD	3
Burke, CA	1
Bauer, WM	1
Lashner, B	1
Rahme, E	1
Barkun, AN	1
Toubouti, Y	1
Bardou, M	1
Hegazi, RA	1
Mady, HH	1
Melhem, MF	1
Sepulveda, AR	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Pilot Study of Toripalimab With or Without Celecoxib as Neoadjuvant Therapy in Resectable Non-metastatic Colorectal Cancer Patients With Mismatch Repair-deficient or Microsatellite Instability-high[NCT03926338]	Phase 1/Phase 2	69 participants (Anticipated)	Interventional	2019-05-10	Recruiting
Prevention of Sporadic Colorectal Adenomas With Celecoxib[NCT00005094]	Phase 3	1,170 participants (Anticipated)	Interventional	2000-03-31	Completed
Effect of Topical Diclofenac on Clinical Outcome in Breast Cancer Patients Treated With Capecitabine: A Randomized Controlled Trial.[NCT05641246]	Phase 2	66 participants (Anticipated)	Interventional	2022-12-08	Active, not recruiting
Phase III Study of the Effects of Selenium on Adenomatous Polyp Recurrence[NCT00078897]	Phase 3	1,621 participants (Actual)	Interventional	2005-01-20	Terminated (stopped due to Concluded - Terminated by PI)
Molecular Targeting of 15-LOX-1 for Apoptosis Induction in Human Colorectal Cancers[NCT00503035]	Phase 2	51 participants (Actual)	Interventional	2003-08-20	Completed
Efficacy of Intra-Articular Injection of Etanercept for Moderate and Severe Knee Osteoarthritis[NCT02722772]		60 participants (Anticipated)	Interventional	2016-02-29	Recruiting
Efficacy of Subcutaneous Injection of Etanercept for Moderate and Severe Knee Osteoarthritis[NCT02722811]		60 participants (Anticipated)	Interventional	2016-02-29	Recruiting
Celecoxib for the Treatment of Non-muscle Invasive Bladder Cancer[NCT02343614]	Phase 2	58 participants (Actual)	Interventional	2003-03-31	Completed
A Phase II, Randomized, Open-label, Controlled, Dose-elevation, Multicenter Trial of an Investigational Drug for the Prevention of Diarrhea Associated With Irinotecan/5FU/Leucovorin Chemotherapy in Patients With Previously Untreated Metastatic Colorectal [NCT00040391]	Phase 2	0 participants	Interventional	2002-06-30	Terminated
Clinical Protocol For a Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Celecoxib (SC-58635) In The Prevention of Colorectal Sporadic Adenomatous Polyps (PRESAP)[NCT00141193]	Phase 3	1,561 participants (Actual)	Interventional	2001-02-28	Completed
A Phase II Of An Optimized LV-5FU-Oxaliplatin Strategy With Celebrex In Metastatic Colorectal Cancer, Optimox2-Celecoxib Study[NCT00072553]	Phase 2	0 participants	Interventional	2003-09-30	Active, not recruiting
Biological-guided Metronomic Chemotherapy as Maintenance Strategy in Responders After Induction Therapy in Metastatic Colorectal Cancer[NCT03158610]	Phase 2/Phase 3	20 participants (Actual)	Interventional	2018-01-29	Terminated (stopped due to Difficult to enrollment patient)
Irinotecan Combined With Infusional 5-FU/Folinic Acid or Capecitabine and the Role of Celecoxib in Patients With Metastatic Colorectal Cancer[NCT00064181]	Phase 3	86 participants (Actual)	Interventional	2003-05-31	Completed
T Cell Mediated Adaptive Therapy for Her2-positive Neoplasms of Digestive System[NCT02662348]	Phase 1	6 participants (Anticipated)	Interventional	2016-02-29	Enrolling by invitation
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Adequate adherence to long-term selenium treatment as measured by blood selenium levels (ng/mL) at one year. (NCT00078897)
Timeframe: One year

Number of Recurrent Adenomas at Surveillance Colonoscopy

Intervention	ng/mL (Median)
Selenium	205.4
Placebo	140.0

Detection of metachronous colorectal adenomas during follow-up, by treatment, in the original cohort. Surveillance colonoscopy is recommended 3 to 5 years after removal of colorectal adenoma(s). Participants will remain on the study intervention until their surveillance colonoscopy. Surveillance colonoscopy is determined by participants' GI physician. (NCT00078897)
Timeframe: 3 to 5 years after baseline colonoscopy

13-HODE Colonic Tissue Levels

Intervention	Adenomas (Number)
Selenium	302
Placebo	295

13-HODE colonic tissue levels measured by Liquid chromatography and tandem mass spectrometry measurements (LC/MS/MS) in colorectal normal and polyp tissues (NCT00503035)
Timeframe: Baseline to post 6 months of celecoxib treatment

PGE2 Colonic Tissue Levels

Intervention	ng/mg tissue protein (Mean)
	polyps before celecoxib treatment	polyps after celecoxib treatment	Normal: before celecoxib treatment	Normal: after celecoxib treatment
Celecoxib	14.56	18.83	23.02	20.03

PGE2 colonic tissue levels measured by Liquid chromatography and tandem mass spectrometry measurements (LC/MS/MS) in colorectal normal and polyp tissues (NCT00503035)
Timeframe: at the baseline colonoscopy (or sigmoidoscopy in patients who had undergone colectomy) before the initiation of celecoxib, and the follow-up colonoscopy or sigmoidoscopy was performed after celecoxib treatment (month 6)

Intervention	ng/mg tissue protein (Mean)
	Polyps: before celecoxib treatment	Polyps: after celecoxib treatment	Normal: before celecoxib treatment	Normal: after celecoxib treatment
Celecoxib	14.71	20.62	21.48	24.99

Article	Year
Selective COX-2 inhibitors do not increase gastrointestinal reactions after colorectal cancer surgery: a systematic review and meta-analysis. BMC gastroenterology, 2023, Aug-14, Volume: 23, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Colorectal Neoplasms; Cyclooxygenase 2 Inhibitor	2023
Clinically Relevant Anti-Inflammatory Agents for Chemoprevention of Colorectal Cancer: New Perspectives. International journal of molecular sciences, 2018, Aug-08, Volume: 19, Issue:8 Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Combined Chemotherapy Protocols; Aspirin; Ce	2018
Germline variants and advanced colorectal adenomas: adenoma prevention with celecoxib trial genome-wide association study. Clinical cancer research : an official journal of the American Association for Cancer Research, 2013, Dec-01, Volume: 19, Issue:23 Topics: Adenoma; Anticarcinogenic Agents; Case-Control Studies; Celecoxib; Colorectal Neoplasms; Female; Gen	2013
Efficacy and safety profile of celecoxib for treating advanced cancers: a meta-analysis of 11 randomized clinical trials. Clinical therapeutics, 2014, Aug-01, Volume: 36, Issue:8 Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cardiovascul	2014
Combination regimen with statins and NSAIDs: a promising strategy for cancer chemoprevention. International journal of cancer, 2008, Sep-01, Volume: 123, Issue:5 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; Atorvastatin; Ce	2008
First-line therapeutic strategies in metastatic colorectal cancer. Oncology (Williston Park, N.Y.), 2008, Nov-30, Volume: 22, Issue:13 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com	2008
Does celecoxib have a role in the treatment of patients with colorectal cancer? Clinical colorectal cancer, 2009, Volume: 8, Issue:1 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Celecoxib; Clinical Trials as	2009
New, long-term insights from the Adenoma Prevention with Celecoxib Trial on a promising but troubled class of drugs. Cancer prevention research (Philadelphia, Pa.), 2009, Volume: 2, Issue:4 Topics: Adenoma; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Cardiovascular System; Ce	2009
Chemoprophylaxis in colorectal cancer: current concepts and a practical algorithm for use. Expert opinion on investigational drugs, 2010, Volume: 19 Suppl 1 Topics: Adenomatous Polyposis Coli; Algorithms; Anticarcinogenic Agents; Celecoxib; Clinical Trials as Topic	2010
Colorectal cancer chemoprevention: is this the future of colorectal cancer prevention? TheScientificWorldJournal, 2012, Volume: 2012 Topics: Adenoma; Adenomatous Polyposis Coli; Adult; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspiri	2012
Colorectal polyps in childhood. Current opinion in pediatrics, 2012, Volume: 24, Issue:5 Topics: Adenomatous Polyps; Adolescent; Age of Onset; Celecoxib; Child; Child, Preschool; Colonic Polyps; Co	2012
Chemoprevention in colorectal neoplasias: what is practical and feasible? Digestive diseases (Basel, Switzerland), 2002, Volume: 20, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Chemoprevention; Colorectal Neoplasms; Cyclooxyg	2002
Chemoprevention of colorectal cancer: slow, steady progress. Cleveland Clinic journal of medicine, 2003, Volume: 70, Issue:4 Topics: Adenomatous Polyposis Coli; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Aspirin;	2003
COX-2 inhibitors in oncology. Seminars in oncology, 2003, Volume: 30, Issue:4 Suppl 12 Topics: Animals; Antineoplastic Agents; Celecoxib; Clinical Trials as Topic; Colorectal Neoplasms; Cyclooxyg	2003
Current and ongoing trials with irinotecan in the United States. Seminars in oncology, 2003, Volume: 30, Issue:4 Suppl 12 Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cap	2003
COX-2 inhibition and colorectal cancer. Seminars in oncology, 2004, Volume: 31, Issue:2 Suppl 7 Topics: Adenomatous Polyposis Coli; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents;	2004
Prevention of colorectal cancer using COX-2 inhibitors: basic science and clinical applications. Frontiers in bioscience : a journal and virtual library, 2004, Sep-01, Volume: 9 Topics: Adenomatous Polyposis Coli; Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Carcinogens	2004
Targeting vascular endothelial growth factor and angiogenesis for the treatment of colorectal cancer. Seminars in oncology, 2005, Volume: 32, Issue:1 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Cel	2005
[Anti-angiogenic therapy for gastrointestinal tumours]. Zeitschrift fur Gastroenterologie, 2005, Volume: 43, Issue:3 Topics: Adult; Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized;	2005
[Non-steroidal anti-inflammatory agents and prevention of colorectal adenomas and carcinomas]. Ugeskrift for laeger, 2006, Jan-23, Volume: 168, Issue:4 Topics: Adenoma; Adenomatous Polyposis Coli; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents;	2006
Compositions for treatment of cancer and inflammation. Recent patents on anti-cancer drug discovery, 2008, Volume: 3, Issue:1 Topics: Apoptosis; Celecoxib; Cell Proliferation; Colorectal Neoplasms; Curcumin; Cyclooxygenase 2 Inhibitor	2008
Cyclooxygenase-2: a target for the prevention and treatment of breast cancer. Endocrine-related cancer, 2001, Volume: 8, Issue:2 Topics: Animals; Breast Neoplasms; Celecoxib; Colorectal Neoplasms; Cyclooxygenase 2; Cyclooxygenase 2 Inhib	2001
Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs. The Journal of clinical investigation, 2001, Volume: 108, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Aspirin; Blood Platelets; Cardiova	2001
[Cyclooxygenase (COX)-2 selective inhibitors: aspirin, a dual COX-1/COX-2 inhibitor, to COX-2 selective inhibitors]. Nihon yakurigaku zasshi. Folia pharmacologica Japonica, 2001, Volume: 118, Issue:3 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Clinical Trials as Topic; Colo	2001
Celecoxib as adjunctive therapy for treatment of colorectal cancer. The Annals of pharmacotherapy, 2001, Volume: 35, Issue:12 Topics: Adenomatous Polyposis Coli; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Chemotherap	2001
[New anti-inflammatory analgetics--are they needed?]. Duodecim; laaketieteellinen aikakauskirja, 1999, Volume: 115, Issue:20 Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Colorectal Neoplasms; Cyclooxygenase 2; Cyclooxy	1999
Celecoxib with chemotherapy in colorectal cancer. Oncology (Williston Park, N.Y.), 2002, Volume: 16, Issue:4 Suppl 3 Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Celecoxib; Clinical Trials as Topic;	2002

Article	Year
Gut-Restricted Selective Cyclooxygenase-2 (COX-2) Inhibitors for Chemoprevention of Colorectal Cancer. Journal of medicinal chemistry, 2021, 08-12, Volume: 64, Issue:15 Topics: Animals; Antineoplastic Agents; Celecoxib; Cell Proliferation; Cell Survival; Colorectal Neoplasms;	2021
CC-01 (chidamide plus celecoxib) modifies the tumor immune microenvironment and reduces tumor progression combined with immune checkpoint inhibitor. Scientific reports, 2022, 01-20, Volume: 12, Issue:1 Topics: Adenocarcinoma; Aminopyridines; Animals; Antibodies, Monoclonal; Benzamides; Celecoxib; Cell Line, T	2022
Thymidine Kinase 1 Mediates the Synergistic Antitumor Activity of Ubenimex and Celecoxib via Regulation of Cell Cycle in Colorectal Cancer. The Journal of pharmacology and experimental therapeutics, 2022, Volume: 382, Issue:2 Topics: Apoptosis; Celecoxib; Cell Cycle; Colorectal Neoplasms; Humans; Leucine; RNA, Messenger; Thymidine K	2022
Human cytomegalovirus infection enhances 5‑lipoxygenase and cycloxygenase‑2 expression in colorectal cancer. International journal of oncology, 2023, Volume: 63, Issue:5 Topics: Arachidonate 5-Lipoxygenase; Caco-2 Cells; Celecoxib; Colorectal Neoplasms; Cyclooxygenase 2; Cytome	2023
Insight into the Colonic Disposition of Sulindac in Humans. Journal of pharmaceutical sciences, 2021, Volume: 110, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Colonic Neoplasms; Colorectal Neoplasms; Humans;	2021
Cyclooxygenase activity mediates colorectal cancer cell resistance to the omega-3 polyunsaturated fatty acid eicosapentaenoic acid. Cancer chemotherapy and pharmacology, 2021, Volume: 87, Issue:2 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Aspirin; Celecoxib; Cell Li	2021
Intracellular AGR2 transduces PGE2 stimuli to promote epithelial-mesenchymal transition and metastasis of colorectal cancer. Cancer letters, 2021, 10-10, Volume: 518 Topics: Animals; Celecoxib; Cell Line; Cell Line, Tumor; Colorectal Neoplasms; Dinoprostone; Epithelial-Mese	2021
The addition of celecoxib improves the antitumor effect of cetuximab in colorectal cancer: role of EGFR-RAS-FOXM1-β- catenin signaling axis. Oncotarget, 2017, Mar-28, Volume: 8, Issue:13 Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; beta Catenin; Blotting, Wes	2017
The effectiveness of cyclooxygenase-2 inhibitors and evaluation of angiogenesis in the model of experimental colorectal cancer. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2018, Volume: 102 Topics: 1,2-Dimethylhydrazine; Animals; Apoptosis; Celecoxib; Colorectal Neoplasms; Cyclooxygenase 2 Inhibit	2018
Prophylactic intervention of probiotics (L.acidophilus, L.rhamnosus GG) and celecoxib modulate Bax-mediated apoptosis in 1,2-dimethylhydrazine-induced experimental colon carcinogenesis. BMC cancer, 2018, Nov-13, Volume: 18, Issue:1 Topics: 1,2-Dimethylhydrazine; Animals; Apoptosis; bcl-2-Associated X Protein; Carcinogenesis; Carcinogens;	2018
c-Met inhibition is required for the celecoxib-attenuated stemness property of human colorectal cancer cells. Journal of cellular physiology, 2019, Volume: 234, Issue:7 Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cell Line, Tumor; Colorectal Neoplasms; Cyclooxy	2019
A nitrophenyl-based prodrug type for colorectal targeting of prednisolone, budesonide and celecoxib. Bioorganic & medicinal chemistry letters, 2013, Mar-15, Volume: 23, Issue:6 Topics: Antineoplastic Agents; Budesonide; Caco-2 Cells; Celecoxib; Cell Membrane Permeability; Clostridium	2013
NSAIDs may regulate EGR-1-mediated induction of reactive oxygen species and non-steroidal anti-inflammatory drug-induced gene (NAG)-1 to initiate intrinsic pathway of apoptosis for the chemoprevention of colorectal cancer. Molecular and cellular biochemistry, 2013, Volume: 378, Issue:1-2 Topics: 1,2-Dimethylhydrazine; Animals; Apoptosis; bcl-X Protein; Celecoxib; Colon; Colorectal Neoplasms; Cy	2013
Sulindac and Celecoxib regulate cell cycle progression by p53/p21 up regulation to induce apoptosis during initial stages of experimental colorectal cancer. Cell biochemistry and biophysics, 2014, Volume: 68, Issue:2 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Binding Sites; Celecoxib; Cell Cycle Ch	2014
In vitro characterization of a liposomal formulation of celecoxib containing 1,2-distearoyl-sn-glycero-3-phosphocholine, cholesterol, and polyethylene glycol and its functional effects against colorectal cancer cell lines. Journal of pharmaceutical sciences, 2013, Volume: 102, Issue:10 Topics: Celecoxib; Cell Line, Tumor; Cell Proliferation; Chemistry, Pharmaceutical; Cholesterol; Colorectal	2013
An apple oligogalactan potentiates the growth inhibitory effect of celecoxib on colorectal cancer. Nutrition and cancer, 2014, Volume: 66, Issue:1 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Caco-2 Cells; Celecoxib; Cell Proliferation	2014
Combinational chemoprevention effect of celecoxib and an oral antiangiogenic LHD4 on colorectal carcinogenesis in mice. Anti-cancer drugs, 2014, Volume: 25, Issue:9 Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Anticarcinogenic Agents; Azoxymethane; Carci	2014
Paeonol exerts an anticancer effect on human colorectal cancer cells through inhibition of PGE₂ synthesis and COX-2 expression. Oncology reports, 2014, Volume: 32, Issue:6 Topics: Acetophenones; Animals; Apoptosis; Caspase 3; Celecoxib; Cell Line, Tumor; Cell Proliferation; Color	2014
Preoperative low dose NSAID treatment influences the genes for stemness, growth, invasion and metastasis in colorectal cancer. International journal of oncology, 2014, Volume: 45, Issue:6 Topics: Anti-Inflammatory Agents, Non-Steroidal; Biomarkers, Tumor; Celecoxib; Colorectal Neoplasms; Female;	2014
In-vitro characterisation of a novel celecoxib microbead formulation for the treatment and prevention of colorectal cancer. The Journal of pharmacy and pharmacology, 2015, Volume: 67, Issue:5 Topics: Celecoxib; Cell Movement; Cell Survival; Chemistry, Pharmaceutical; Colorectal Neoplasms; Drug Deliv	2015
Simultaneous inhibition of EGFR/VEGFR and cyclooxygenase-2 targets stemness-related pathways in colorectal cancer cells. PloS one, 2015, Volume: 10, Issue:6 Topics: Apoptosis; Caco-2 Cells; Celecoxib; Cell Cycle; Cell Proliferation; Colorectal Neoplasms; Cyclooxyge	2015
Wnt/β-catenin pathway regulates MGMT gene expression in cancer and inhibition of Wnt signalling prevents chemoresistance. Nature communications, 2015, Nov-25, Volume: 6 Topics: Animals; Antineoplastic Agents; Benzeneacetamides; beta Catenin; Brain Neoplasms; Camptothecin; Cele	2015
The effect of celecoxib and its combination with imatinib on human HT-29 colorectal cancer cells: Involvement of COX-2, Caspase-3, VEGF and NF-κB genes expression. Cellular and molecular biology (Noisy-le-Grand, France), 2016, Feb-29, Volume: 62, Issue:2 Topics: Antineoplastic Agents; Apoptosis; Caspase 3; Celecoxib; Cell Survival; Colorectal Neoplasms; Cycloox	2016
Expression of Endoglin and Vascular Endothelial Growth Factor as Prognostic Markers in Experimental Colorectal Cancer. Anticancer research, 2016, Volume: 36, Issue:8 Topics: Adenocarcinoma; Animals; Biomarkers, Tumor; Celecoxib; Colorectal Neoplasms; Cyclooxygenase 2 Inhibi	2016
HSP90 inhibitor enhances anti-proliferative and apoptotic effects of celecoxib on HT-29 colorectal cancer cells via increasing BAX/BCL-2 ratio. Cellular and molecular biology (Noisy-le-Grand, France), 2016, Oct-31, Volume: 62, Issue:12 Topics: Apoptosis; bcl-2-Associated X Protein; Benzoquinones; Blotting, Western; Celecoxib; Cell Proliferati	2016
Cyclooxygenase inhibitors down regulate P-glycoprotein in human colorectal Caco-2 cell line. Pharmaceutical research, 2008, Volume: 25, Issue:9 Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transport	2008
Celecoxib induces p53-PUMA pathway for apoptosis in human colorectal cancer cells. Chemico-biological interactions, 2008, Oct-22, Volume: 176, Issue:1 Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Celecoxib; Cell Death; Cell Line, T	2008
Patient preferences for the chemoprevention of colorectal cancer. Digestive diseases and sciences, 2009, Volume: 54, Issue:10 Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Colorectal Neo	2009
Comment re: "Sporadic aberrant crypt foci are not a surrogate endpoint for colorectal adenoma prevention" and "Aberrant crypt foci in the adenoma prevention with celecoxib trial". Cancer prevention research (Philadelphia, Pa.), 2008, Volume: 1, Issue:3 Topics: Adenoma; Antineoplastic Agents; Biomarkers; Celecoxib; Chemoprevention; Clinical Trials as Topic; Co	2008
A reciprocal relationship exists between non-steroidal anti-inflammatory drug-activated gene-1 (NAG-1) and cyclooxygenase-2. Cancer letters, 2009, Sep-18, Volume: 282, Issue:2 Topics: Animals; Celecoxib; Colorectal Neoplasms; Cyclooxygenase 2; Dinoprostone; Gene Expression Regulation	2009
18F-FLT and 18F-FDG PET to measure response to radiotherapy combined with celecoxib in two colorectal xenograft models. International journal of radiation biology, 2009, Volume: 85, Issue:9 Topics: Animals; Celecoxib; Cell Line, Tumor; Colorectal Neoplasms; Cyclooxygenase 2; Cyclooxygenase 2 Inhib	2009
PC-407, a celecoxib derivative, inhibited the growth of colorectal tumor in vitro and in vivo. Cancer science, 2009, Volume: 100, Issue:12 Topics: Animals; Antineoplastic Agents; Apoptosis; beta Catenin; Celecoxib; Cell Line, Tumor; Colorectal Neo	2009
Inhibition of azoxymethane-induced colorectal cancer by CP-31398, a TP53 modulator, alone or in combination with low doses of celecoxib in male F344 rats. Cancer research, 2009, Oct-15, Volume: 69, Issue:20 Topics: Adenocarcinoma; Animals; Apoptosis; Azoxymethane; Blotting, Western; Carcinogens; Celecoxib; Cell Pr	2009
Celecoxib-induced apoptosis is enhanced by ABT-737 and by inhibition of autophagy in human colorectal cancer cells. Autophagy, 2010, Volume: 6, Issue:2 Topics: Apoptosis; Autophagy; bcl-2-Associated X Protein; Biphenyl Compounds; Caspases; Celecoxib; Cell Line	2010
The role of NF-κB and PPARγ in experimentally induced colorectal cancer and chemoprevention by cyclooxygenase-2 inhibitors. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2010, Volume: 31, Issue:5 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Blotting, Western; Celecoxib; Colorectal Neoplasms	2010
Chemopreventive effects of non-steroidal anti-inflammatory drugs in early neoplasm of experimental colorectal cancer: an apoptosome study. Journal of gastrointestinal cancer, 2011, Volume: 42, Issue:4 Topics: 1,2-Dimethylhydrazine; Aberrant Crypt Foci; Animals; Anti-Inflammatory Agents, Non-Steroidal; Apopto	2011
Chemoprevention, risk reduction, therapeutic prevention, or preventive therapy? Journal of the National Cancer Institute, 2010, Dec-15, Volume: 102, Issue:24 Topics: Adenoma; Anticarcinogenic Agents; Breast Neoplasms; Carcinoma, Basal Cell; Carcinoma, Squamous Cell;	2010
Of timing and surrogates: a way forward for cancer chemoprevention. Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Jun-01, Volume: 17, Issue:11 Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Antineoplastic Agents; Biomarkers;	2011
Gene expression following exposure to celecoxib in humans: pathways of inflammation and carcinogenesis are activated in tumors but not normal tissues. Digestion, 2011, Volume: 84, Issue:3 Topics: Adenocarcinoma; Celecoxib; Cell Cycle; Cell Transformation, Neoplastic; Colonic Polyps; Colorectal N	2011
Celecoxib induces cell apoptosis coupled with up-regulation of the expression of VEGF by a mechanism involving ER stress in human colorectal cancer cells. Oncology reports, 2011, Volume: 26, Issue:2 Topics: Apoptosis; Celecoxib; Cell Growth Processes; Cell Line, Tumor; Colorectal Neoplasms; Endoplasmic Ret	2011
Non steroidal anti-inflammatory drugs modulate the physicochemical properties of plasma membrane in experimental colorectal cancer: a fluorescence spectroscopic study. Molecular and cellular biochemistry, 2011, Volume: 358, Issue:1-2 Topics: 1,2-Dimethylhydrazine; 2-Naphthylamine; Animals; Anti-Inflammatory Agents, Non-Steroidal; Blotting,	2011
Cardiovascular risk markers and mechanisms in targeting the COX pathway for colorectal cancer prevention. Cancer prevention research (Philadelphia, Pa.), 2011, Volume: 4, Issue:8 Topics: Adenoma; Anticarcinogenic Agents; C-Reactive Protein; Celecoxib; Colorectal Neoplasms; Female; Human	2011
Cost-effectiveness of aspirin, celecoxib, and calcium chemoprevention for colorectal cancer. Clinical therapeutics, 2011, Volume: 33, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Anticarcinogenic Agents; Calcium; Celecoxib; Colorectal Neoplasms; C	2011
COX-2-independent induction of apoptosis by celecoxib and polyamine naphthalimide conjugate mediated by polyamine depression in colorectal cancer cell lines. International journal of colorectal disease, 2012, Volume: 27, Issue:7 Topics: Acetyltransferases; Amino Acid Chloromethyl Ketones; Apoptosis; Caspases; Celecoxib; Cell Line, Tumo	2012
Role of Sulindac and Celecoxib in chemoprevention of colorectal cancer via intrinsic pathway of apoptosis: exploring NHE-1, intracellular calcium homeostasis and Calpain 9. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2012, Volume: 66, Issue:2 Topics: 1,2-Dimethylhydrazine; Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Calcium; Calpain	2012
A further piece of the puzzle: positive FOBT, colonoscopy, aspirin and the prevention of colorectal cancer. Digestion, 2012, Volume: 85, Issue:4 Topics: Aspirin; Celecoxib; Chemoprevention; Colonoscopy; Colorectal Neoplasms; Cyclooxygenase Inhibitors; E	2012
Downregulation of Prominin 1/CD133 expression in colorectal cancer by NSAIDs following short-term preoperative treatment. International journal of oncology, 2012, Volume: 41, Issue:1 Topics: AC133 Antigen; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Antigens, CD; Bioma	2012
Antitumor and anti-metastatic effects of cyclooxygenase-2 inhibition by celecoxib on human colorectal carcinoma xenografts in nude mouse rectum. Oncology reports, 2012, Volume: 28, Issue:3 Topics: Animals; Antineoplastic Agents; Apoptosis; Celecoxib; Colorectal Neoplasms; Cyclooxygenase 2; Cycloo	2012
Angiostatic properties of sulindac and celecoxib in the experimentally induced inflammatory colorectal cancer. Cell biochemistry and biophysics, 2013, Volume: 66, Issue:2 Topics: 1,2-Dimethylhydrazine; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Cele	2013
New studies highlight benefit of Xeloda in new combination treatments for colorectal cancer. Expert review of anticancer therapy, 2002, Volume: 2, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Celecoxib; Clinical Tria	2002
Effect of celecoxib on capecitabine-induced hand-foot syndrome and antitumor activity. Oncology (Williston Park, N.Y.), 2002, Volume: 16, Issue:12 Suppl N Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Capecitabine; Celecoxib; Colorectal Neoplasms;	2002
The cyclooxygenase-2-selective inhibitors rofecoxib and celecoxib prevent colorectal neoplasia occurrence and recurrence. Gastroenterology, 2003, Volume: 125, Issue:2 Topics: Adenoma; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Case-Control Studies; Cel	2003
Celecoxib and rofecoxib potentiate chronic colitis and premalignant changes in interleukin 10 knockout mice. Inflammatory bowel diseases, 2003, Volume: 9, Issue:4 Topics: Animals; Celecoxib; Colitis; Colorectal Neoplasms; Cyclooxygenase Inhibitors; Disease Models, Animal	2003
The 15-lipoxygenase-1 product 13-S-hydroxyoctadecadienoic acid down-regulates PPAR-delta to induce apoptosis in colorectal cancer cells. Proceedings of the National Academy of Sciences of the United States of America, 2003, Aug-19, Volume: 100, Issue:17 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Arachidonate 15-Lipoxygenase; Base Sequ	2003
Combination of a poxvirus-based vaccine with a cyclooxygenase-2 inhibitor (celecoxib) elicits antitumor immunity and long-term survival in CEA.Tg/MIN mice. Cancer research, 2004, May-15, Volume: 64, Issue:10 Topics: Animals; B-Lymphocytes; Cancer Vaccines; Carcinoembryonic Antigen; Celecoxib; Colorectal Neoplasms;	2004
The cost-effectiveness of aspirin versus cyclooxygenase-2-selective inhibitors for colorectal carcinoma chemoprevention in healthy individuals. Cancer, 2004, Jul-01, Volume: 101, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Colorectal Neoplasms; Computer Simulati	2004
Comparison of the anti-proliferation and apoptosis-induction activities of sulindac, celecoxib, curcumin, and nifedipine in mismatch repair-deficient cell lines. Journal of the Formosan Medical Association = Taiwan yi zhi, 2004, Volume: 103, Issue:8 Topics: Antineoplastic Agents; Apoptosis; Celecoxib; Cell Cycle; Cell Line, Tumor; Chemoprevention; Colorect	2004
Extracolonic manifestations of familial adenomatous polyposis after proctocolectomy. Archives of surgery (Chicago, Ill. : 1960), 2005, Volume: 140, Issue:2 Topics: Adenomatous Polyposis Coli; Adolescent; Adult; Celecoxib; Colectomy; Colorectal Neoplasms; Comorbidi	2005
Tumor-associated down-regulation of 15-lipoxygenase-1 is reversed by celecoxib in colorectal cancer. Annals of surgery, 2005, Volume: 241, Issue:6 Topics: Adenoma; Apoptosis; Arachidonate 15-Lipoxygenase; Blotting, Western; Carcinoma; Celecoxib; Colorecta	2005
Monocyte chemoattractant protein 1 and macrophage cyclooxygenase 2 expression in colonic adenoma. Gut, 2006, Volume: 55, Issue:1 Topics: Adenoma; Adult; Aged; Aged, 80 and over; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Ce	2006
The role of cyclooxygenase-2 in mediating the effects of histamine on cell proliferation and vascular endothelial growth factor production in colorectal cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Oct-01, Volume: 11, Issue:19 Pt 1 Topics: Aged; Aged, 80 and over; Blotting, Western; Caco-2 Cells; Celecoxib; Cell Line, Tumor; Cell Prolifer	2005
Antitumor efficacy of capecitabine and celecoxib in irradiated and lead-shielded, contralateral human BxPC-3 pancreatic cancer xenografts: clinical implications of abscopal effects. Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Dec-15, Volume: 11, Issue:24 Pt 1 Topics: 5'-Nucleotidase; Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Capecitabi	2005
The COX-2 story: is any drug completely "safe?". Gastroenterology, 2006, Volume: 130, Issue:1 Topics: Celecoxib; Clinical Trials as Topic; Colorectal Neoplasms; Cyclooxygenase 2 Inhibitors; Humans; Prod	2006
Celecoxib leads to G2/M arrest by induction of p21 and down-regulation of cyclin B1 expression in a p53-independent manner. European journal of cancer (Oxford, England : 1990), 2006, Volume: 42, Issue:3 Topics: Animals; Celecoxib; Colorectal Neoplasms; Cyclin B; Cyclin-Dependent Kinase Inhibitor p21; Cyclooxyg	2006
Luminal delivery and dosing considerations of local celecoxib administration to colorectal cancer. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2006, Volume: 28, Issue:3 Topics: Adhesiveness; Animals; Celecoxib; Cell Survival; Chemistry, Pharmaceutical; Chitosan; Colorectal Neo	2006
Effects of cyclooxygenase-2 inhibition on serum and tumor gastrins and expression of apoptosis-related proteins in colorectal cancer. Digestive diseases and sciences, 2006, Volume: 51, Issue:4 Topics: Adenocarcinoma; Aged; Apoptosis Regulatory Proteins; Base Sequence; Biomarkers, Tumor; Biopsy, Needl	2006
Celecoxib can induce cell death independently of cyclooxygenase-2, p53, Mdm2, c-Abl and reactive oxygen species. Anti-cancer drugs, 2006, Volume: 17, Issue:6 Topics: Adenocarcinoma; Animals; Antioxidants; Apoptosis; Blotting, Western; Breast Neoplasms; Celecoxib; Ce	2006
Risks and benefits of celecoxib to prevent recurrent adenomas. The New England journal of medicine, 2006, Aug-31, Volume: 355, Issue:9 Topics: Adenoma; Adenomatous Polyps; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celec	2006
Risk and risk reduction involving arginine intake and meat consumption in colorectal tumorigenesis and survival. International journal of cancer, 2007, Feb-01, Volume: 120, Issue:3 Topics: Acetyltransferases; Adult; Aged; Aged, 80 and over; Animals; Anti-Inflammatory Agents, Non-Steroidal	2007
Celecoxib and CVS risk--lessons from the APC and PreSAP studies. Rheumatology (Oxford, England), 2007, Volume: 46, Issue:4 Topics: Adenoma; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Colorectal Neo	2007
Risks and benefits of celecoxib to prevent colorectal adenomas. The New England journal of medicine, 2006, Nov-30, Volume: 355, Issue:22 Topics: Adenoma; Cardiovascular Diseases; Celecoxib; Colorectal Neoplasms; Cyclooxygenase 2 Inhibitors; Huma	2006
Is the demonstration of adenoma reduction with rofecoxib a pyrrhic victory? Gastroenterology, 2006, Volume: 131, Issue:6 Topics: Adenoma; Celecoxib; Chemoprevention; Colonoscopy; Colorectal Neoplasms; Cyclooxygenase 2 Inhibitors;	2006
Celecoxib and curcumin additively inhibit the growth of colorectal cancer in a rat model. Digestion, 2006, Volume: 74, Issue:3-4 Topics: Analysis of Variance; Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Biopsy, Needle; C	2006
The adenoma prevention with celecoxib and prevention of colorectal sporadic adenomatous polyps trials: stepping stones to progress. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2007, Volume: 16, Issue:2 Topics: Adenomatous Polyps; Celecoxib; Colorectal Neoplasms; Cyclooxygenase Inhibitors; Dose-Response Relati	2007
Letter by Cen regarding article, "Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas". Circulation, 2007, Mar-27, Volume: 115, Issue:12 Topics: Adenoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Celecoxib; Color	2007
Activation of p38 mitogen-activated protein kinase by celecoxib oppositely regulates survivin and gamma-H2AX in human colorectal cancer cells. Toxicology and applied pharmacology, 2007, Jul-01, Volume: 222, Issue:1 Topics: Apoptosis; Blotting, Western; Caspase 3; Celecoxib; Cell Count; Cell Cycle; Cell Line, Tumor; Cell S	2007
Chemoprevention with special reference to inherited colorectal cancer. Familial cancer, 2008, Volume: 7, Issue:1 Topics: Adenomatous Polyposis Coli; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Ascorbic	2008
Targeting cyclooxygenase-2 and the epidermal growth factor receptor for the prevention and treatment of intestinal cancer. Cancer research, 2007, Oct-01, Volume: 67, Issue:19 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Combined Chemotherapy Protocols; Ce	2007
Gene expression analysis proposes alternative pathways for the mechanism by which celecoxib selectively inhibits the growth of transformed but not normal enterocytes. Clinical cancer research : an official journal of the American Association for Cancer Research, 2007, Nov-15, Volume: 13, Issue:22 Pt 1 Topics: Animals; Anticarcinogenic Agents; Celecoxib; Cell Line, Transformed; Cell Proliferation; Chemopreven	2007
Chemoprevention of arylamine-induced colorectal aberrant crypts. Experimental biology and medicine (Maywood, N.J.), 2008, Volume: 233, Issue:1 Topics: Aminobiphenyl Compounds; Animals; Anticarcinogenic Agents; Celecoxib; Colorectal Neoplasms; Cyclooxy	2008
Celecoxib inhibits growth of tumors in a syngeneic rat liver metastases model for colorectal cancer. Cancer chemotherapy and pharmacology, 2008, Volume: 62, Issue:5 Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; Caspase 3; Celecoxib; Cell Survival; Colo	2008
Atorvastatin and celecoxib: a future role in cancer chemoprevention. International journal of cancer, 2008, Aug-01, Volume: 123, Issue:3 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Antineoplastic Agents; A	2008
COX-2-specific inhibition: implications for clinical practice. The Journal of the American Osteopathic Association, 1999, Volume: 99, Issue:11 Suppl Topics: Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Blood Platelets; Celecoxib; Colorectal N	1999
Prevention of colorectal cancer: tumor progression, chemoprevention, and COX-2 inhibition. Gastroenterology, 2000, Volume: 119, Issue:1 Topics: Animals; Celecoxib; Colorectal Neoplasms; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygen	2000
Celecoxib prevents tumor growth in vivo without toxicity to normal gut: lack of correlation between in vitro and in vivo models. Cancer research, 2000, Nov-01, Volume: 60, Issue:21 Topics: Animals; Anticarcinogenic Agents; Apoptosis; Celecoxib; Cell Cycle; Cell Division; Colorectal Neopla	2000
Surveillance colonoscopy or chemoprevention with COX-2 inhibitors in average-risk post-polypectomy patients: a decision analysis. Alimentary pharmacology & therapeutics, 2001, Volume: 15, Issue:5 Topics: Adenoma; Aged; Celecoxib; Chemoprevention; Colonic Polyps; Colonoscopy; Colorectal Neoplasms; Cost-B	2001
Targeting cyclooxygenase 2 and HER-2/neu pathways inhibits colorectal carcinoma growth. Gastroenterology, 2001, Volume: 120, Issue:7 Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemothe	2001
COX-2 inhibitors: cancer trials test new uses for pain drug. Journal of the National Cancer Institute, 2002, Feb-20, Volume: 94, Issue:4 Topics: Anticarcinogenic Agents; Antineoplastic Agents; Celecoxib; Clinical Trials as Topic; Colorectal Neop	2002
Studies on the development of colon-targeted delivery systems for celecoxib in the prevention of colorectal cancer. Journal of drug targeting, 2002, Volume: 10, Issue:3 Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Calorimetry, Differential Sc	2002

celecoxib and Colorectal Cancer